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Synthetic antibody protein mimics of inﬂiximab by
molecular scaﬀolding on novel CycloTriVeratrilene
(CTV) derivatives†
Ondřej Longin, Mohammed Hezwani, Helmus van de Langemheen and
Rob M. J. Liskamp *
Syntheses of novel semi-orthogonally protected CycloTriVeratrilene (CTV) analogues with enhanced
water solubility, that is 3 and 4, derived from the previously described CTV scaﬀold derivative 2 are
described here. These scaﬀolds 2–4 enabled a sequential introduction of three diﬀerent complementarity
determining region (CDR) mimics via Cu(I)-catalysed azide–alkyne cycloaddition towards medium-sized
protein mimics denoted as “synthetic antibodies”. The highly optimised sequential introduction enabled
selective attachment of three diﬀerent CDR mimics in a one-pot fashion. This approach of obtaining syn-
thetic antibodies, demonstrated by the synthesis of paratope mimics of monoclonal antibody inﬂiximab
(Remicade®), provided a facile access to a range of (highly) pre-organised molecules bearing three
diﬀerent (cyclic) peptide segments and may ﬁnd a wide range of applications in the ﬁeld of protein–
protein interaction disruptors as well as in the development of synthetic vaccines or lectin mimics. The
prepared synthetic antibodies were tested for their aﬃnity towards tumour necrosis factor alpha using
surface plasmon resonance and synthetic antibodies with micromolar aﬃnities were uncovered.
Introduction
For several years we have been interested in the molecular con-
struction and further development of protein mimics toward
medium-sized molecule alternatives of biologics such as anti-
bodies and vaccines.1–4 In this area, we are facing several
important challenges, which may determine a successful
outcome of this quest. One challenge of our continuous atten-
tion is the development of pre-organized molecular scaﬀolds
as the core molecular unit for attaching complementarity
determining region (CDR)-loops mimics. This goes hand-in-
hand with our desire to develop scalable syntheses. In these
endeavours we are increasingly faced with a limited or even
poor solubility of our molecular constructs. With respect to this,
it is of course realised that an important condition for the use
of any bio-active compound is an adequate solubility in an
aqueous environment. In fact a (very)poor water solubility or
insolubility is responsible for the largest attrition rate of mole-
cule candidates in the drug discovery process.5 If it turns out to
be impossible to improve water solubility by chemical modifi-
cation, then depending on the drug candidate, more sophisti-
cated drug delivery approaches are called for. Thus, the solubi-
lity issue is a crucial challenge in our approaches and if it can
be dealt with in an early stage of molecular construction of our
protein mimics, this is a preferred route. Concomitantly,
convenience and scalability of synthesis remain very important
issues in the assembly of these medium-size molecules.
Although paratope mimics consisting of a single CDR loop
have recently been reported to be successful as synthetic anti-
body mimics,6 molecular construction of mimics having more
than one cyclic peptide mimicking the individual CDR loops
may still be very beneficial for their aﬃnity and selectivity.1,2
Recently, we described4 the synthesis of the first semi-
orthogonally protected derivative of a highly pre-organized CTV
scaﬀold 1 (Fig. 1), the CTV scaﬀold derivative 2 (Fig. 2) onto
which three diﬀerent peptide segments representing CDR loops
can be sequentially introduced. Furthermore, a convenient
“click and cleavage” approach was presented for the sequential
introduction of the three diﬀerent CDR loop mimics onto this
scaﬀold derivative towards the synthesis of synthetic antibodies.
Although synthesis of relatively complex synthetic anti-
bodies could be achieved quite conveniently, the water solubi-
lity of the resulting protein mimic was rather low. Hence, in
order to improve water solubility and thus facilitate sub-
sequent evaluation of synthetic antibodies, the semi-orthog-
onally protected CTV scaﬀold derivatives 3 and 4 (Fig. 2) with
improved water solubility were developed. In addition, the
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c8ob01104d
School of Chemistry, Joseph Black Building, University of Glasgow, University Avenue,
Glasgow G12 8QQ, UK and Department of Pharmaceutical Sciences,
Faculty of Science, Utrecht University, P.O. Box 80082, NL-3508 TB Utrecht,
The Netherlands. E-mail: Robert.liskamp@glasgow.ac.uk
This journal is © The Royal Society of Chemistry 2018 Org. Biomol. Chem.
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Ju
ne
 2
01
8.
 D
ow
nl
oa
de
d 
on
 7
/9
/2
01
8 
11
:0
9:
33
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal
incorporation of a mono or diethylene glycol spacer (MEG or
DEG) will indicate whether it is necessary to allow more space
for accommodation of the CDR loop mimics, since they are
significantly larger than the CTV scaﬀold itself and an
elongated spacer may provide additional room. To obtain
some insight into the structure of these CTV derivatives, mole-
cular models were constructed using the Maestro (http://www.
schrödinger.com) modelling suite in which MacroModel soft-
ware was incorporated (Fig. 3). These molecular models
(without silyl protecting groups) clearly show the pre-organized
bowl shape of all three CTV derivatives. In addition the mono
ethylene glycol moieties containing CTV derivative 3 may, next
to increasing water solubility, provide some room for the rela-
tively large peptide loops to be attached. In the model of the
diethylene glycol moieties containing CTV derivative 4, likely
increased water solubility due to the diethylene glycol
moieties, may reduce the pre-organization of the molecular
construct, because of their increased flexibility.
Furthermore, the previously described “click and cleavage”
protocol for synthesis of synthetic antibodies, which required
purification and lyophilisation after each step of synthesis, has
been optimised in such degree that purification and lyophilisa-
tion is only required at the very end of the synthesis. Moreover,
the optimised one-pot protocol includes splitting of the reac-
tion mixture towards the end of synthesis allowing for two
diﬀerent synthetic antibodies to be prepared simultaneously.
These changes significantly reduced time required for syn-
thesis of synthetic antibodies and greatly improved the overall
yield of synthesis. Thus, two synthetic antibodies have now
been prepared within only 28 hours with overall yield of 12%
to 21%, corresponding to 65% to 73% per step of the five-step
synthesis.
This optimised protocol was applied in the synthesis of syn-
thetic antibodies, which mimic the paratope of monoclonal
antibody (mAb) infliximab (Remicade®). Infliximab is a clini-
cally used biologic for treatment of human tumour necrosis
factor alpha (hTNFα) mediated autoimmune diseases and
directly binds to hTNFα. Cyclised versions of CDRs of the para-
tope, i.e. CDR mimics 28–31, were introduced on the CTV
scaﬀold derivatives 2, 3 and 4 to yield a collection of synthetic
antibodies comprising of 12 compounds. The ability of the
prepared synthetic antibodies to bind to hTNFα was tested by
Surface Plasmon Resonance (SPR) using expressed hTNFα
immobilised on a CM5 chip. The best hTNFα-binder, antibody
mimic 36, exhibited a KD of 11 μM.
Fig. 2 Previously prepared semi-orthogonally protected CTV scaﬀold derivative 2 and the newly synthesised mono and diethylene glycol spacer
containing analogues 3 and 4.
Fig. 1 CTV scaﬀold enantiomers.
Fig. 3 Molecular models of CTV derivatives 2–4 (without TES and TIPS protecting groups) showing their pre-organization and possible inﬂuence of
the mono or diethylene glycol moieties.
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Results and discussion
The recent development of a semi-orthogonally protected
CycloTriVeratrylene (CTV) scaﬀold derivative 2 opened up the
way towards design and synthesis of other semi-orthogonally
protected CTV scaﬀold derivatives with altered physico-chemi-
cal properties; that is mono and diethylene glycol spacer con-
taining CTV scaﬀold derivatives 3 and 4.
The required (oligo)ethylene glycol linkers for alkylation of
the CTV scaﬀold, i.e. linkers of a and b series, were prepared
by similar synthetic pathways (Schemes 1 and 2). Firstly, mono
ethylene glycol 6a and diethylene glycol 6b were treated with
sodium hydride and potassium tert-butoxide, respectively, fol-
lowed by a treatment with propargyl bromide to yield the
corresponding propargyl ether derivatives 7a and 7b. Next, the
hydroxyl group of propargyl containing derivatives 7a,b was
protected with dihydropyran to provide tetrahydropyranyl
(THP) protected derivatives 8a,b. Then, the free alkyne was sily-
lated with triethylsilyl (TES) chloride or triisopropylsilyl (TIPS)
chloride using n-butyl lithium as a base to yield TES and TIPS
protected derivatives 9a,b and 10a,b, respectively. Finally, the
THP protected hydroxyl groups of the derivatives 9a,b and 10a,
b were converted into bromides using bromine and triphenyl-
phospine to give the desired TES 11a,b and TIPS 12a,b pro-
tected alkylation linkers. The linker derivatives 13a and 13b
bearing unprotected alkyne moieties were prepared from
derivatives 7a and 8b by conversion of free or the THP pro-
tected hydroxyl groups into iodide and bromide, respectively.
After this CTV scaﬀold 1 was prepared according to the pro-
cedure of Canceill et al.7 Protection of CTV scaﬀold 1 as a di-
tetrahydropyranyl (diTHP) derivative 14 as well as the recovery
of CTV scaﬀold 1 from side products of the protection was per-
formed as previously described.4 Alkylation of diTHP protected
scaﬀold 14 with (oligo)ethylene glycol linkers 13a,b was per-
formed in acetonitrile in the presence of Cs2CO3 to yield
monoalkylated diTHP protected CTV scaﬀold derivative 15a,b
(Scheme 3) in high yield. Following the removal of THP pro-
tecting groups with 1 M HCl in methanol (Scheme 3), the di-
hydroxyl CTV scaﬀold derivatives 16a,b were alkylated with TIPS
protected linkers 12a,b (Scheme 4) providing rather modest
yields of the desired monoTIPS derivatives 17a,b along with
unwanted diTIPS side products 18a,b (Scheme 4) while leaving
some of the dihydroxyl CTV scaﬀold 16a,b unreacted. Finally,
the TES protected linkers 11a,b were introduced to monoTIPS
CTV scaﬀold derivatives 17a,b in DMF using Cs2CO3 as a base
to yield the semi-orthogonally protected CTV scaﬀold derivatives
3 and 4 (Scheme 4). In case of the CTV scaﬀold derivative 3 a
hydrolysis of TES protecting group and therefore formation of a
side product 5 lacking the TES protecting group was observed.
Improvement of aqueous solubility by incorporation of
ethylene glycol spacers
Since silyl groups are not present in the final products, i.e. syn-
thetic antibodies, aqueous solubility of the desilylated ana-
logues 20, 21, and 22 (Scheme 5) of CTV scaﬀold derivatives 2,
3, and 4, respectively, were determined, by measurement of
dissolved quantities using reverse phase HPLC.
Indeed, incorporation of the (oligo)ethylene glycol linkers
improved water solubility as the mono-ethylene glycol deriva-
tive 21 and diethylene glycol derivative 22 were found to be 5
and 14 times more soluble in deionised water (supplementedScheme 1 Synthesis of silyl protected alkylation linkers 11a,b and 12a,b.
Scheme 2 Synthesis of free alkyne bearing alkylation linkers 13a and 13b.
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with 2% of ethanol) than CTV scaﬀold derivative 20 without a
solubilizing linker.
Unfortunately, improvement of the solubility of the
synthetic antibodies containing these CTV derivatives in PBS
buﬀer pH 7.4 was not suﬃcient to allow for their biological
activity evaluation on cell lines. The prepared synthetic anti-
bodies were reasonably soluble in 2-(N-morpholino)ethanesul-
fonic acid hydrate (MES) buﬀer pH 6.0 containing 5% DMSO.‡
Log P determination
Log P values of the desilylated analogues 20, 21, and 22 were
also determined using an Organisation for Economic Co-oper-
ation and Development (OECD) approved reverse phase HPLC
method.8 Log P values of 4.1, 4.3, and 4.6 were determined for
compounds 20, 22 and 21, respectively. The similar log P values
indicate that the resulting protein mimics will have similar cell
permeability properties and ensuing biological activity pro-
perties, which are not influenced by variation of the scaﬀold.
CDRs selection and peptide cyclisation
As was described previously4 selection of peptide sequences
mimicking CDRs of the paratope of mAb infliximab
Scheme 3 Indirect monoalkylation of CTV scaﬀold.
Scheme 4 Introduction of TIPS/TES protected linkers onto monoalkylated CTV scaﬀold.
Scheme 5 Synthesis of desilylated analogues 20, 21, 22 of CTV scaﬀold derivatives 2, 3, and 4.
‡A few of the synthetic antibody constructs derived from CTV scaﬀold derivative 2
tended to precipitate from the solution within several hours of solution preparation.
Nevertheless, this time frame still allowed for carrying out the SPR experiments.
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Scheme 6 Synthesis and cyclisation of linear CDR mimics.
Fig. 4 CDR loops in inﬂiximab based on reported interactions between hTNFα and inﬂiximab Fab.9 The colour coding corresponds to the peptides
in the CDR mimics and toward the molecular synthetic antibody constructs. A top view (interaction site with hTNFα) and a side view are shown. The
residue (Arg-52, Heavy chain), which was part of the red and green loop, is salmon-coloured.
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(Remicade®) was based on the X-ray crystal structure9 of a
complex of infliximab with hTNFα trimer. In this research,
selection of CDR mimics was extended by including peptide
segment 23 (Scheme 6) as its cyclised derivative 28. This particu-
lar sequence has been shown to be crucial for binding to
human hTNFα as was demonstrated by a mutation study.9
Thus, a total of four peptide segments which mimic the selected
CDRs were prepared. Three sequences, 23, 24, 26, correspond to
the sequences present in the entire peptide segment of the CDR
loops of infliximab. Peptide sequence 25 mainly consists of dis-
tinct amino acid residues present in the antibody which are
important for binding to hTNFα as is apparent from the X-ray
structure of the complex and which are in close spatial proxi-
mity to target amino acids in hTNFα. These peptide segments
of the CDRs of infliximab are shown in colour (Fig. 4), which
corresponds to the colours of the CDR loop mimics 28–31 used
in the construction of the synthetic antibodies.
The selected peptide sequences were furnished with both
an N and a C terminal cysteine residue to allow their chemo-
selective cyclisation using our recently developed polar hinge
2710 (Scheme 5) which should enhance water solubility of the
cyclised peptides. The resulting azide handle containing
cyclized peptides 28–31 were subsequently introduced via
Cu(I)-catalyzed azide alkyne cycloaddition (CuAAC) onto the
CTV scaﬀold derivatives 2, 3 and 4 as will be described below.
One-pot synthesis of synthetic antibodies
From the very start of this research, it was our desire to ulti-
mately develop synthesis protocols for these medium-size mole-
cules, which could be conveniently reproduced and applied also
by researchers not directly working in the peptide field. Our
recent CTV scaﬀold based protein mimic was assembled in a
“click and cleavage” approach with several intermediate purifi-
cations.4 Here, this approach was extended to a one-pot pro-
cedure where the CDR loop mimics were subsequently intro-
duced on each of the CTV scaﬀolds 2, 3 or 4. For clarity: only
one CTV scaﬀold derivative was used in each reaction and not a
mixture of 2–4. After introduction of the first and second CDR
loop mimic the silyl protecting groups were removed and only
after complete assembly the antibody mimics were purified.
Thus, one equivalent of CDR loop mimic 31 was introduced
via CuAAC onto one equivalent of either CTV scaﬀold deriva-
tive 2, 3, or 4 (Scheme 7) to give a one CDR loop containing
protein mimic. Immediately thereafter, silver nitrate was
Scheme 7 One-pot synthetic approach towards synthetic antibodies 35–40.
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added to the reaction mixture to selectively remove the TES
protecting group11 and without intermediate purification the
next CDR-mimicking peptide loop 30 was introduced via
CuAAC leading to the two CDR loop mimic containing CTV
derivatives. During this reaction aminoguanidine hydro-
chloride was added as a scavenger of the formed dehydroascor-
bic acid i.e.12 to prevent formation of ascorbic acid adducts
with arginine residues in the peptide loops. Next, TBAF·3H2O
was added to remove the TIPS protecting group giving two
loop containing protein mimic intermediates 32, 33, 34 and
the reaction mixture was split into two equal portions. To one
portion, 1.2 equivalents of CDR loop mimic 29 were added
while to the other, 1.2 equivalents of CDR loop mimic 28 were
added. Thereby in a convenient manner two diﬀerent synthetic
antibodies were prepared. Upon completion of this one-pot
procedure, the reaction mixtures were concentrated and the
antibody mimics were purified by semi-preparative HPLC.
By using this same one-pot procedure albeit changing the
sequences of addition of the various CDR-mimicking peptide
loops to CTV scaﬀold derivative 2, 3, or 4 the other antibody
mimics 44–49 were prepared (Scheme 8). Thus, CDR loop
mimic 29 was introduced onto either scaﬀold 2, 3, or 4 via
CuAAC, followed by removal of TES group with silver nitrate and
subsequent introduction of the CDR mimic 28 before TIPS pro-
tecting group was removed with TBAF·3H2O to give intermedi-
ates 41, 42, 43. After splitting of the reaction mixture in two
equal parts, CDR loop mimic 30 was added to one part of the
mixture while CDR loop mimic 31 was added to the other part.
Hence, the described approach led to a collection of twelve
protein mimics 35–40 and 44–49 designated as “synthetic anti-
bodies” (Fig. 5). This collection comprised all possible combi-
nations of the four CDR loop mimics 28–31 onto each of the
CTV scaﬀold derivatives 2, 3 or 4.
Progress of conversion of the CTV derivatives by subsequent
peptide loop introduction was conveniently monitored by
analytical reversed phase HPLC as the retention times of the
intermediate products were suﬃciently diﬀerent (Fig. 6). As
was apparent from the chromatograms, the reaction mixture
remained very clean until the introduction of the third CDR
loop mimic when side products, undesired combinations of
previously unreacted CDR mimics on CTV scaﬀold derivative,
with retention times close to that of the desired synthetic anti-
body mimic started to appear. Nevertheless, these side pro-
ducts could be largely separated with an optimised gradient
Scheme 8 One-pot synthetic approach towards synthetic antibodies 44–49.
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Fig. 5 Prepared collection of antibody mimics toward synthetic antibodies.
Fig. 6 Representative analytical HPLC chromatogram of the one-pot synthesis of synthetic antibodies – overlay of the entire reaction sequence for
synthetic antibody 37. Black (A) – product after introduction of CDR mimic 31 onto CTV scaﬀold derivative 4. Green (B) – product after TES protect-
ing group removal. Blue (C) – product after introduction of CDR mimic 30. Red (D) – product after TIPS protecting group removal. Orange (E) –
product after introduction of CDR mimic 29. Peak at tR = 21.8 min represents TBTA.
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on a preparative C8 reversed phase column. Thus, the desired
protein mimics were obtained in purities of 91%–96%.
Surface plasmon resonance
Initially, binding studies of protein mimics were attempted
using Isothermal Titration Calorimetry (ITC). However, these
were unsuccessful because of the need to dialyse hTNFα and
synthetic antibodies to exactly match DMSO concentration (2%
of final volume of appropriate buﬀer) in separately prepared
samples and thus to avoid an artificial DMSO signal.
Unfortunately, it was found that the synthetic antibodies stick
to the cellulose dialysis membrane and as a consequence dis-
appear from solution. Therefore binding studies of the pre-
pared synthetic antibodies 35–40 and 44–49 were carried out
by Surface Plasmon Resonance (SPR) on immobilised hTNFα.
The integrity of immobilised hTNFα was first verified by
flowing an anti-hTNFα specific monoclonal antibody (Life
Technologies, Thermo Fisher Scientific, clone 68B 2B3) over
the chip surface and indeed was capable of interacting with
immobilised hTNFα (KD = 32 nM). After an initial screening of
the prepared protein mimics at 2 μM (runs in duplicate) posi-
tive hits, i.e. compounds exhibiting binding, were selected and
their binding characteristics were further determined. A repre-
sentative sensogram of the best binding synthetic antibody 36
(Fig. 7) as well as kinetic parameters of synthetic antibodies
35, 36, 44, 47, and 48 (Table 1) are shown below.
The common crucial feature of synthetic antibodies 35, 36,
37, 44, 47, 48 and 49, capable of binding hTNFα, was the pres-
ence of CDR (red loop) mimic 29. CDR (green loop) mimic 31
proved to be important too as it was present in all synthetic
antibodies capable of successfully binding to hTNFα except for
synthetic antibody 44 which contained CDR (orange loop) 30
instead next to (red loop) mimic 29. In general, incorporation
of combinations of CDR mimics (red loop) 29 and (green loop)
31 together with either CDR mimic (blue loop) 28 or (orange
loop) 30 in a synthetic antibody led to antibody mimics with
micromolar range aﬃnity for hTNFα. Based on the obtained
KD values (Table 1), the combination of CDR mimic (red loop)
29, (orange loop) 30, (green loop) 31 has slightly better aﬃnity
for hTNFα than combination of CDR mimics (blue loop) 28,
(red loop) 29, (green loop) 31. Incorporation of the combi-
nation of CDR mimics (blue loop) 28 and (orange loop) 30 into
a synthetic antibody resulted generally in lack of binding of
the corresponding synthetic antibodies to hTNFα, i.e. 38, 39,
40, 45 and 46, with the exception of construct 44, which still
displayed a decent aﬃnity (KD = 66 μM). Upon closer examin-
ation of this phenomenon supported by modelling (Fig. 8) it
was concluded that CDR mimic (blue loop) 28 and (orange
loop) 30 originate from an overlapping region of infliximab
and thus may interfere with each other resulting in the lack of
binding for hTNFα. This however is not the case for synthetic
antibody 44 where the absence of an ethylene glycol linker
might have prevented this interference.
Synthetic antibodies derived from CTV scaﬀolds 2 or 3
capable of binding hTNFα, had a kinetic profile suitable for
fitting of the measured curves. Synthetic antibodies derived
from CTV scaﬀold derivative 4 had too fast kinetics (koﬀ greater
than 1 × 10−1 s−1) to reliably determine their dissociation con-
stant. This might be due to a higher flexibility, of the diethylene
glycol spacer, resulting in an increase of flexibility, possibly
leading to a decrease in binding aﬃnity. This is also apparent
from Fig. 3 showing that the diethylene glycol spacer may lead
to less directionality, so that the loops are gathered more around
the CTV scaﬀold, rather than pointing in the same direction.
In view of the above results it was not entirely surprising
that CDR (green loop) mimic 31 by itself showed aﬃnity for
hTNFα nevertheless the measured kinetics was too fast to
reliably obtain a dissociation constant. However, the other
three CDR mimics including the CDR (red loop) 29, had no
aﬃnity for hTNFα whatsoever. As anticipated, a multivalent
eﬀect induced by attachment of the appropriate CDR mimics
on suitable CTV scaﬀold derivatives, resulting in increased
aﬃnities was observed. This also clearly demonstrated the
crucial role of CTV scaﬀold derivatives in the molecular con-
struction of antibody mimics by covalent assembly of individ-
ual CDR loop mimics.
Conclusion
A new one-pot approach allowing for rapid synthesis of syn-
thetic antibodies has been described. The approach was
applied in the construction of a collection of synthetic anti-
body candidates mimicking the paratope of mAb infliximab
(Remicade®). The ability of the synthetic antibodies to mimic
the original monoclonal antibody infliximab was determined
by measuring their binding to hTNFα, using SPR. SPR
measurements showed that 7 out of 12 prepared synthetic anti-
body candidates were capable of binding hTNFα with 5 of
them displaying dissociation constants ranging from 11 μM to
66 μM. The relatively strong binding with a KD of 11 μM clearly
supported the validity of the concept of molecular scaﬀolding
of CDR mimics towards possible synthetic antibodies.
Fig. 7 Sensogram representing binding of synthetic antibody 36 to
immobilised hTNFα. Raw data presented.§
§Selected data, cleaned and fitted with heterogeneous ligand binding model,
are included in the ESI.†
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Since the synthetic antibodies are prepared from racemic
CTV, diastereomers of the synthetic antibodies have been
obtained. However, it is likely that the size the attached CDR
loop mimics will mask the diﬀerence between the enantio-
meric CTV moieties.
Moreover, in this approach the rather low water solubility of
the previously reported4 semi-orthogonally protected CTV
scaﬀold derivative 2 was addressed by synthesising its mono-
ethylene and diethylene glycol spacer containing analogues 3
and 4 respectively. Although incorporation of the glycol
spacers did improve water solubility 5 times and 14 times
respectively, these improvements were not suﬃcient for dis-
solution of these synthetic antibodies in PBS buﬀer pH 7.4 to
allow bio-activity evaluation on cell lines. Therefore, under
present investigation is further improvement of the water solu-
bility of CTV derivatives.
In conclusion, the concept of replacing the majority of the
structure of a monoclonal antibody by a molecular scaﬀold
capable of performing a similar structural functional role as in
the parent antibody leading to a significantly smaller protein
Fig. 8 Molecular models of the synthetic antibody protein mimics 36 (top-left), 35 (top-right), 48 (bottom-left) and 37 (bottom-right). The ﬁrst
three are the best binding candidates. Molecular construct 37 is included to compare the inﬂuence of the diethylene glycol moiety with the con-
structs 36 and 35 having a mono ethylene glycol moiety or none, respectively. The weak aﬃnity for immobilized hTNFα by 37 might be explained by
the increased ﬂexibility of the diethylene glycol moieties not allowing an optimal multivalent interaction.
Table 1 Obtained kinetic parameters for interaction of synthetic antibodies with immobilized hTNFα
Average values of 2 experiments performed in duplicate (n = 2) reported.
Paper Organic & Biomolecular Chemistry
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mimic has proven to be valid. The obtained protein mimics
denoted as a “synthetic antibodies” have less than 4% of
the molecular mass of the mimicked monoclonal antibody
infliximab. Nevertheless, the aﬃnity of the prepared protein
mimics is still considerably lower than that of the original
monoclonal antibody, but the obtained micromolar range
aﬃnity might indicate that in addition to room for improve-
ment, that this is a promising approach. It is realised, however
that synthesis of these fairly complex molecular constructs has
to be continuously improved if not simplified. In this work,
considerable strides have been made toward significantly
improving the synthesis of these protein mimics in terms of
time and eﬃciency.
Two synthetic antibodies have been conveniently prepared
in less than 30 hours while only requiring semi-preparative
reverse phase HPLC purification at the very end of the syn-
thesis. Thus, this synthetic protocol is a great improvement
compared to our previously described methods for CTV
scaﬀold derivatives as well as other TAC and related
scaﬀolds,3,4,13 which required semi-preparative HPLC purifi-
cation and isolation after practically each step of the synthesis
of corresponding protein mimics, in total 4 times or 5 times.
Furthermore, this protocol enabled attachment of three
diﬀerent ligands/substituents to one single molecule via Cu(I)-
mediated azide–alkyne cycloaddition in a one pot reaction.
Application of this protocol can however go beyond the intro-
duction of peptide loops leading to synthetic antibodies as vir-
tually any azide handle containing small or larger ligand can
be introduced onto the CTV scaﬀold derivatives 2, 3, and 4 for
example carbohydrates, nucleic acids and small molecules or
combinations of these, giving rise to synthetic vaccines, mole-
cular constructs interacting with carbohydrate binding pro-
teins (lectins), covalent multi-enzyme complexes, enzyme
mimics etc.
Experimental part
General information
All analytical or HPLC grade chemicals and solvents were pur-
chased from commercial sources and were used as received
unless stated otherwise. 1H NMR and the 13C NMR spectra
were recorded on a Bruker AVIII 400 MHz or 500 MHz
Spectrospin spectrometer in CDCl3. Chemical shifts (δ) are
reported in parts per million (ppm) relative to trimethylsilane
(TMS, 0.00 ppm) or CDCl3 (7.26 ppm). TLC was carried out on
silica gel plates (Merck 60F254) and visualization was carried
out by both UV detection (254 nm) and staining (cerium
molybdenate, potassium permanganate) followed by heating.
For column chromatography, silica gel Geduran® Si
60 (40–63 μm) was used. Dry solvents (THF, CH2Cl2) were dis-
pensed from Pure Solv™ 500 Solvent Purification System and
other dry solvents (acetonitrile, DMF) were obtained from
freshly opened commercially available HPLC grade solvents by
removal of residual water with activated 4 Å molecular sieves
overnight. HRMS-ESI was recorded on Bruker microTOFq High
Resolution Mass Spectrometer in the positive mode. EI-MS was
recorded on Jeol MSTATION JMS-700 in the positive mode.
Commercial solutions of n-butyl lithium were titrated using
diphenyl acetic acid to determine their actual concentration
prior to use. Degassed solvents for synthesis of synthetic anti-
bodies were obtained upon sonication of the solvents in degas
mode for 30 minutes while purging the headspace with nitro-
gen stream trough septum. Petroleum ether used refers to a
mixture with boiling point of 40 °C–60 °C.
Fmoc-amino acids were obtained from Activotec
(Cambridge, United Kingdom) and N,N,N′,N′-tetramethyl-O-(6-
chloro-1H-benzotriazol-1-yl)uranium hexafluorophosphate
(HCTU) was obtained from Matrix Innovation (Quebec,
Canada). Tentagel S RAM resin (particle size 90 μm, capacity
0.25 mmol g−1) was obtained from IRIS Biotech (Marktredwitz,
Germany). Methyl tert-butyl ether (MTBE), n-hexane (HPLC
grade) and TFA were obtained from Aldrich (Milwaukee, USA).
DMF (Peptide grade) was obtained from VWR (Lutterworth,
United Kingdom). Piperidine and DiPEA were obtained from
AGTC Bioproducts (Hessle, United Kingdom), and 1,2-ethane-
dithiol (EDT) was obtained from Merck (Darmstadt, Germany).
HPLC grade CH2Cl2 and acetonitrile were obtained from
Fischer Scientific (Loughborough, United Kingdom). Solid
phase peptide synthesis was performed on a PTI Tribute-UV
peptide synthesizer. Lyophilisations were performed on a
Christ Alpha 2–4 LDplus apparatus. Analytical high pressure
liquid chromatography (HPLC) was carried out on a Shimadzu
instrument comprising a communication module (CBM-20A),
autosampler (SIL-20HT), pump modules (LC-20AT), UV/Vis
detector (SPD-20A) and system controller (Labsolutions V5.54
SP), with a Phenomenex Gemini C18 column (110 Å, 5 μm,
250 × 4.60 mm). UV measurements were recorded at 214 and
254 nm, using a standard protocol: 100% buﬀer A (aceto-
nitrile/H2O 5 : 95 with 0.1% TFA) for 2 min followed by a linear
gradient of buﬀer B (acetonitrile/H2O 95 : 5 with 0.1% TFA) into
buﬀer A (0–100%) over 30 min at a flow rate of 1.0 mL min−1.
Purification of synthetic antibodies was performed on
an Agilent Technologies 1260 infinity preparative system using
UV detector with a Dr Maisch C8 column (110 Å, 10 μm, 250 ×
20 mm) starting with 100% buﬀer A for 10 min followed by a
linear gradient of buﬀer B into buﬀer A (27–37%) over 40 min
at a flow rate of 10.0 mL min−1. CDR mimics were purified on
the same system using Phenomenex Gemini C18 column
(110 Å, 10 μm, 250 × 20 mm) starting with 100% buﬀer A for
5 min followed by and linear gradient of buﬀer B into buﬀer A
(gradient specified for each compound) over 60 min at a flow
rate of 12.5 mL min−1. The buﬀers had same composition as
described for analytical HPLC. Auto-collection of fractions was
based on the UV measurements at 214 nm. One-pot reaction
mixtures were analysed by taking 10 μL of the reaction
mixture, removing solvent under stream of nitrogen, dissolving
the dried residue in buﬀer A/buﬀer B (1/1 v/v, 500 μL) and
injecting of 50 μL of the obtained solution on analytical HPLC.
Liquid chromatography mass spectrometry (LCMS) was carried
out on a Thermo Scientific LCQ Fleet quadrupole mass
spectrometer with a Dionex Ultimate 3000 LC using a
Organic & Biomolecular Chemistry Paper
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Dr Maisch Reprosil Gold 120 C18 column (110 Å, 3 μm, 150 ×
4.0 mm), using a 0–100% linear gradient of buﬀer B into
buﬀer A and the same flow rate and buﬀers as described for
analytical HPLC. Deionised water was obtained on Milli-Q®
station (Merck Millipore).
Alkylation linker synthesis and CTV scaﬀold derivatisation
Propargyl-MEG-OH 7a. Compound 7a was prepared accord-
ing to a modified literature procedure.14 To a solution of
Anhydrous ethylene glycol 6a (15.0 mL, 271 mmol) in dry THF
(20 mL), NaH (2.71 g, 67.8 mmol, 60% dispersion in mineral
oil) was added portion wise under nitrogen stream. Once
hydrogen formation ceased, propargyl bromide (7.31 mL
(67.8 mmol) of a 80 wt% solution in toluene) was slowly added
and the resulting reaction mixture was stirred for 2 h at 45 °C.
Then the reaction mixture was diluted with CH2Cl2 (250 mL)
and washed with water (250 mL). The aqueous layer was
extracted with CH2Cl2 (125 mL) and combined organic layers
were dried over MgSO4, filtered, and CH2Cl2 was removed
under reduced pressure. The crude product was purified by
column chromatography (n-hexane/Et2O 6/4 to Et2O).
Compound 7a (2.0 g, 33%) was obtained as a yellow oil. Rf =
0.43 (n-hexane/EtOAc 1/1). 1H-NMR (400 MHz, CDCl3): δ = 2.44
(t, J = 2.4 Hz, 1H), 2.47 (t, J = 5.2 Hz, 1H), 3.61–3.63 (m, 2H),
3.72–3.75 (m, 2H), 4.18 (d, J = 2.4 Hz, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 58.5, 61.7, 71.3, 74.8, 79.6. The characterisation of
this compound has also been previously reported.15
O-THP-propargyl-MEG 8a. Compound 8a was prepared
according to a literature procedure.16 To a solution of com-
pound 7a (2.03 g, 20.3 mmol) in dry CH2Cl2 (20 mL), DHP
(1.94 mL, 21.3 mmol) was added and the reaction mixture was
cooled to 0 °C. Next, p-TsOH·H2O (0.04 g, 0.20 mmol) was
added to the reaction mixture which was then allowed to warm
to RT and stirred for 4 h. Then, the reaction mixture was
washed with aqueous saturated NaHCO3 (30 mL), the aqueous
phase was extracted with CH2Cl2 (10 mL) and the combined
organic layers were dried over MgSO4, filtered, and CH2Cl2 was
removed under reduced pressure with the water bath kept at
RT (19 °C–21 °C). The crude product was purified by column
chromatography (n-hexane/Et2O 8/2). Compound 8a (3.3 g,
87%) was obtained as a yellowish oil. Rf = 0.72 (n-hexane/
EtOAc 7/3). 1H-NMR (400 MHz, CDCl3): δ = 1.48–1.63 (m, 4H),
1.68–1.86 (m, 2H), 2.42 (t, J = 2.4 Hz, 1H), 3.46–3.52 (m, 1H),
3.59–3.64 (m, 1H), 3.70–3.72 (m, 2H), 3.83–3.90 (m, 2H), 4.23
(t, J = 2.3 Hz, 2H), 4.61–4.63 (m, 1H). 13C-NMR (100 MHz,
CDCl3): δ = 19.6, 25.5, 30.6, 58.5, 62.4, 66.6, 69.2, 74.5, 79.9,
99.0. HRMS-ESI: m/z calcd for C10H16NaO3 [M + Na]
+,
207.0992; found, 207.0993. The characterisation of this com-
pound has also been previously reported.17
O-THP-(TES)propargyl-MEG 9a. Compound 9a was prepared
according to a modified literature procedure.18 A solution of
compound 8a (2.30 g, 12.5 mmol) in dry THF (35 mL) was
cooled to −78 °C (solid CO2/acetone). Next, n-BuLi (5.50 mL,
13.1 mmol, 2.4 M in hexanes) was added slowly dropwise and
the reaction mixture was stirred under nitrogen atmosphere at
−78 °C for 1 h before TES-Cl (2.31 mL, 13.8 mmol) was added.
Dropwise addition of n-butyl lithium had to very slow (at least
over 10 min) otherwise also silylation of the propargyl methyl-
ene occurred. The reaction mixture was then allowed to warm
up to RT and stirred under a nitrogen atmosphere for an
additional 4 h before it was quenched by addition of an
aqueous saturated NH4Cl solution (30 mL). The reaction
mixture was extracted with Et2O (50 mL and 25 mL) and the
combined organic layers were dried over MgSO4, filtered, and
Et2O was removed under reduced pressure with the water bath
kept at RT (19 °C–21 °C). The crude product was purified by
column chromatography (n-hexane/Et2O 98/2 to n-hexane/Et2O
9/1). Compound 9a (3.1 g, 82%) was obtained as yellowish oil.
Rf = 0.44 (n-hexane/EtOAc 9/1).
1H-NMR (400 MHz, CDCl3): δ =
0.58 (q, J = 8.1 Hz, 6H), 0.97 (t, J = 8.1 Hz, 9H), 1.46–1.64 (m,
4H), 1.66–1.85 (m, 2H), 3.45–3.51 (m, 1H), 3.59–3.64 (m, 1H),
3.69–3.72 (m, 2H), 3.83–3.85 (m, 2H), 4.21 (d, J = 1.5 Hz, 2H),
4.63 (t, J = 3.5 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 4.4,
7.5, 19.5, 25.5, 30.6, 59.2, 62.3, 66.5, 68.9, 88.8, 98.9, 102.8.
HRMS-ESI: m/z calcd for C16H30NaO3Si [M + Na]
+, 321.1856;
found, 321.1842.
O-THP-(TIPS)propargyl-MEG 10a. Compound 10a was pre-
pared according to a modified literature procedure.18 A solu-
tion of compound 8a (2.30 g, 12.5 mmol) in dry THF (35 mL)
was cooled to −78 °C (solid CO2/acetone). Next, n-BuLi
(6.05 mL, 13.1 mmol, 2.2 M in hexanes) was added slowly
dropwise and the reaction mixture was stirred under nitrogen
atmosphere at −78 °C for 1 h before TIPS-Cl (3.07 mL,
14.4 mmol) was added. Dropwise addition of n-butyl lithium
had to very slow (at least over 10 min) otherwise also silylation
of the propargyl methylene occurred. Then the procedure
described for compound 9a was followed. The crude product
was purified by column chromatography (n-hexane/Et2O 95/5
to n-hexane/Et2O 8/2). Compound 10a (2.9 g, 68%) was
obtained as a yellowish oil. Rf = 0.46 (n-hexane/EtOAc 9/1).
1H-NMR (400 MHz, CDCl3): δ = 1.04 (m, 21H), 1.46–1.62
(m, 4H), 1.66–1.86 (m, 2H), 3.45–3.51 (m, 1H), 3.59–3.63 (m,
1H), 3.71–3.74 (m, 2H), 3.81–3.89 (m, 2H), 4.23 (d, J = 1.1 Hz,
2H), 4.62 (t, J = 3.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ =
11.2, 18.7, 19.5, 25.6, 30.6, 59.2, 62.2, 66.5, 68.7, 87.6, 98.9,
103.5. HRMS-ESI: m/z calcd for C19H36NaO3Si [M + Na]
+,
363.2326; found, 363.2313.
(TES)propargyl-MEG bromide 11a. Compound 11a was pre-
pared according to a modified literature procedure.18 Br2
(370 μL, 7.04 mmol) was added dropwise at 0 °C to a solution
of Ph3P (1.94 g, 7.39 mmol) in dry CH2Cl2 (28 mL) and the
solution was stirred under nitrogen atmosphere for 30 min
during which a white precipitate was formed. Next, compound
9a (2.10 g, 7.04 mmol) was added dropwise and the reaction
mixture was stirred under nitrogen atmosphere at 0 °C for
additional 4.5 h during which the white precipitate dissolved.
The reaction mixture was then diluted with water (30 mL) and
extracted with CH2Cl2 (30 mL and 15 mL). The combined
organic layers were washed with aqueous saturated NaHCO3
(30 mL), dried over MgSO4, filtered, and CH2Cl2 was removed
under reduced pressure with the water bath kept at RT (19 °C–
21 °C). The crude product was purified by column chromato-
Paper Organic & Biomolecular Chemistry
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graphy (n-hexane/Et2O 98/2). Compound 11a (1.75 g, 90%) was
obtained as a colourless oil. Rf = 0.57 (n-hexane/Et2O 95/5).
1H-NMR (400 MHz, CDCl3): δ = 0.61 (q, J = 7.9 Hz, 6H), 0.99 (t,
J = 7.9 Hz, 9H), 3.51 (t, J = 6.2 Hz, 2H), 3.87 (t, J = 6.2 Hz, 2H),
4.25 (s, 2H). 13C-NMR (100 MHz, CDCl3): δ = 4.3, 7.5, 30.2,
59.1, 69.5, 89.7, 102.0. HRMS-ESI: m/z calcd for
C11H21NaOSi
79Br [M + Na]+, 299.0437; found, 299.0425.
(TIPS)propargyl-MEG bromide 12a. Compound 12a was pre-
pared according to a modified literature procedure.18 Br2
(380 μL, 7.34 mmol) was added dropwise at 0 °C to a solution
of Ph3P (2.02 g, 7.71 mmol) in dry CH2Cl2 (29 mL) and the
solution was stirred under nitrogen atmosphere for 30 min
during which a white precipitate was formed. Next, compound
10a (2.50 g, 7.34 mmol) was added dropwise and the reaction
mixture was stirred under nitrogen atmosphere at 0 °C for
additional 4.5 h during which the white precipitate dissolved.
Then the procedure described for compound 11a was followed.
The crude product was purified by column chromatography
(n-hexane to n-hexane/Et2O 99/1). Compound 12a (1.9 g, 83%)
was obtained as a colourless oil. Rf = 0.61 (n-hexane/Et2O 95/5).
1H-NMR (400 MHz, CDCl3): δ = 1.08 (m, 21H), 3.51 (t, J =
6.1 Hz, 2H), 3.89 (t, J = 6.1 Hz, 2H), 4.27 (s, 2H). 13C-NMR
(100 MHz, CDCl3): δ = 11.1, 18.6, 30.1, 59.0, 69.3, 88.4, 102.6.
HRMS-ESI: m/z calcd for C14H27NaOSi
79Br [M + Na]+, 341.0907;
found, 341.0900.
Propargyl-MEG iodide 13a. Compound 13a was prepared
according to a literature procedure.19 I2 (2.74 g, 10.8 mmol)
was added to a solution of Ph3P (2.83 g, 10.8 mmol) and imid-
azole (740 mg, 10.8 mmol) in dry CH2Cl2 (6.4 mL) at 0 °C.
Next, a solution of compound 7a (830 mg, 8.30 mmol) in
CH2Cl2 (0.6 mL) was added to the reaction mixture and the
resulting orange suspension was allowed to warm up to RT
and stirred for 2 h. Then, the formed precipitate was removed
by filtering over Celite®, washed with CH2Cl2 and CH2Cl2 was
removed from the filtrate under reduced pressure. The crude
product was purified by column chromatography (pentane to
pentane/Et2O 99/1). Compound 13a (1.6 g, 91%) was obtained
as a colourless oil, which slowly crystallised upon storage in a
fridge. Rf = 0.56 (n-hexane/Et2O 9/1).
1H-NMR (400 MHz,
CDCl3): δ = 2.46 (t, J = 2.4 Hz, 1H), 3.27 (t, J = 6.8 Hz, 2H), 3.80
(t, J = 6.8 Hz, 2H), 4.21 (d, J = 2.4 Hz, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 2.3, 58.1, 70.5, 75.1, 79.3. EI-MS: m/z calcd for
C5H7OI [M]
+, 210; found, 210. The characterisation of this
compound has also been previously reported.20
Di(O-THP)-O-MEG-propargyl CTV 15a. To a solution of
diTHP protected CTV scaﬀold 14 (3.20 g, 5.55 mmol) in aceto-
nitrile (28 mL), Cs2CO3 (2.17 g, 6.66 mmol) was added, fol-
lowed by addition of a solution of alkyne bromide 13a (1.51 g,
7.21 mmol) in acetonitrile (1 mL) and the resulting reaction
mixture was stirred for 27 h. Next, the formed solid was
removed by filtering over Celite®, washed with CH2Cl2 and the
solvents were removed under reduced pressure. Crude com-
pound 15a (3.8 g) was obtained as a yellow foam. An aliquot
was purified for analysis by column chromatography
(n-hexane/EtOAc 7/3 to n-hexane/EtOAc 1/1) giving compound
15a as a white foam. Rf = 0.56 (n-hexane/EtOAc 1/1).
1H-NMR
(500 MHz, CDCl3): δ = 1.56–1.70 (m, 6H), 1.83–1.95 (m, 4H),
1.99–2.07 (m, 2H), 2.46 (m, 1H), 3.49–3.58 (m, 5H), 3.81–3.85
(m, 9H), 3.87–3.89 (m, 3H), 4.00–4.05 (m, 1H), 4.14–4.20 (m,
2H), 4.26 (m, 2H), 4.70–4.73 (m, 3H), 5.18–5.23 (m, 1H),
5.41–5.44 (m, 1H), 6.84–6.86 (m, 3H), 6.91–6.93 (m, 1H),
7.13–7.17 (m, 2H). 13C-NMR (125 MHz, CDCl3): δ = 18.7, 19.0,
25.3, 30.4, 30.5, 36.3, 36.4, 36.5, 55.9, 56.0, 56.2, 56.4, 56.5,
56.6, 56.7, 58.5, 61.9, 62.2, 68.3, 69.0, 74.7, 79.7, 97.1, 97.2,
98.2, 98.3, 113.6, 113.7, 113.8, 114.0, 114.3, 114.4, 114.6, 116.5,
116.6, 116.7, 116.8, 118.6, 118.7, 118.9, 119.0, 119.6, 119.9,
120.0, 131.4, 131.6, 131.7, 131.8, 131.9, 132.1, 132.2, 132.3,
133.1, 133.2, 133.3, 133.4, 133.8, 133.9, 134.0, 144.9, 145.0,
145.1, 145.2, 146.6, 146.7, 148.6, 149.0. HRMS-ESI: m/z calcd
for C39H46NaO9 [M + Na]
+, 681.3034; found, 681.3008.
O-MEG-propargyl CTV-diOH 16a. To a solution of crude
compound 15a (3.8 g) in MeOH (100 mL), 1 M HCl (5 mL) was
added dropwise resulting in a yellow solution. The reaction
mixture was stirred for 40 min after which TLC showed com-
plete deprotection of 15a. Next, MeOH was removed under
reduced pressure and the remaining slurry was dissolved in
CHCl3 (150 mL) and washed with water (125 mL). Afterwards,
the aqueous phase was extracted with CHCl3 (75 mL and
50 mL) and the combined organic layers were dried over
MgSO4, filtered, and CHCl3 was removed under reduced
pressure. The crude product was purified by column chromato-
graphy (n-hexane/EtOAc 6/4 to n-hexane/EtOAc 4/6).
Compound 16a (2.5 g, 92% over 2 steps, 96% per step) was
obtained as a brownish foam. Rf = 0.22 (n-hexane/EtOAc 1/1).
1H-NMR (400 MHz, CDCl3): δ = 2.46 (t, J = 2.4 Hz, 1H),
3.43–3.52 (m, 3H), 3.77–3.84 (m, 9H), 3.88 (t, J = 5.0 Hz, 2H),
4.10–4.20 (m, 2H), 4.25 (d, J = 2.3 Hz, 2H), 4.61–4.72 (m, 3H),
5.58 (s, 1H), 5.60 (s, 1H), 6.77 (s, 1H), 6.79 (s, 1H), 6.82 (s, 1H),
6.90 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 36.3, 36.4, 56.0,
56.2, 58.5, 68.4, 69.1, 74.8, 79.7, 112.3, 113.9, 115.6, 116.7,
131.2, 131.3, 132.0, 132.6, 133.1, 144.2, 145.3, 146.7, 148.6.
HRMS-ESI: m/z calcd for C29H30NaO7 [M + Na]
+, 513.1884;
found, 513.1872.
O-MEG-propargyl-O-MEG-(TIPS)propargyl CTV-OH 17a. To a
solution of compound 16a (2.47 g, 5.04 mmol) in DMF
(66 mL), Cs2CO3 (2.13 g, 6.55 mmol) was added, followed by
addition of a solution of TIPS-protected alkyne bromide 12a
(1.77 g, 5.54 mmol) in DMF (10 mL) and the resulting reaction
mixture was stirred for 22 h until the majority of compound
12a was consumed (based on TLC – cerium molybdenate
stain). Next, DMF was removed under reduced pressure and
the viscous residue was dissolved in EtOAc (400 mL) and
washed with aqueous 1 M KHSO4 (400 mL). Next, the aqueous
phase was extracted with EtOAc (100 mL) and the combined
organic layers were washed with aqueous 1 M LiCl (2 ×
100 mL) for eﬃcient DMF removal, dried over MgSO4, filtered,
and EtOAc was removed under reduced pressure. The crude
product was purified by column chromatography (n-hexane/
EtOAc 7/3 to n-hexane/EtOAc 3/7). Compound 17a (1.4 g, 37%)
was obtained as a yellowish foam. Rf = 0.28 (n-hexane/EtOAc
6/4). 1H-NMR (400 MHz, CDCl3): δ = 1.06 (m, 21H), 2.43 (m,
1H), 3.49 (d, J = 13.8 Hz, 3H), 3.81 (s, 6H), 3.83 (s, 3H),
Organic & Biomolecular Chemistry Paper
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3.85–3.92 (m, 4H), 4.11–4.21 (m, 4H), 4.23 (s, 2H), 4.28 (d, J =
1.6 Hz, 2H), 4.63–4.75 (m, 3H), 5.48 (s, 1H), 6.78 (s, 1H), 6.81
(m, 2H), 6.88–6.91 (m, 3H). 13C-NMR (100 MHz, CDCl3): δ =
11.2, 18.6, 36.3, 36.5, 56.2, 56.3, 56.4, 58.6, 59.3, 68.1, 68.4,
69.1, 74.7, 79.6, 87.8, 103.2, 112.3, 113.8, 113.9, 114.0, 114.1,
115.7, 116.7, 116.9, 131.2, 131.7, 132.1, 132.4, 132.9, 133.0,
133.2, 144.2, 145.3, 146.8, 146.9, 147.0, 148.7. HRMS-ESI: m/z
calcd for C43H56NaO8Si [M + Na]
+, 751.3637; found, 751.3606.
Compound 18a, a side product, (760 mg, 16%) was obtained
as a colourless amorphous solid. Rf = 0.61 (n-hexane/EtOAc
6/4). 1H-NMR (400 MHz, CDCl3): δ = 1.06 (m, 42H), 2.43 (t, J =
2.4 Hz, 1H), 3.51 (d, J = 13.7 Hz, 3H), 3.82 (s, 9H), 3.85–3.91
(m, 6H), 4.11–4.20 (m, 6H), 4.24 (d, J = 2.4 Hz, 2H), 4.28 (s,
4H), 4.72 (d, J = 13.6 Hz, 3H), 6.82 (s, 3H), 6.91 (s, 3H).
13C-NMR (100 MHz, CDCl3): δ = 11.2, 18.6, 36.5, 56.3, 56.4,
58.5, 59.3, 68.1, 69.0, 74.7, 79.6, 87.8, 103.2, 114.0, 114.1,
116.7, 131.9, 132.9, 133.0, 146.9, 147.0, 148.6. HRMS-ESI: m/z
calcd for C57H82NaO9Si2 [M + Na]
+, 989.5390; found, 989.5367.
The starting material 16a (520 mg, 21%) was recovered.
O-MEG-propargyl-O-MEG-(TIPS)propargyl-O-MEG-(TES)pro-
pargyl CTV 3. To a solution of compound 17a (1.34 g,
1.84 mmol) in dry DMF (18 mL) 10 beads of activated 4 Å
sieves were added and the resulting solution was stirred under
nitrogen atmosphere. After 1 h Cs2CO3 (660 mg, 2.02 mmol)
was added, followed by the addition of TES-protected alkyne
bromide 11a (610 mg, 2.21 mmol) and the resulting reaction
mixture was stirred under nitrogen atmosphere for a week
during which additional Cs2CO3 (587 mg, 1.80 mmol) and
compound 11a (500 mg, 1.80 mmol) were added in order to
increase conversion. Then, DMF was removed under reduced
pressure and the viscous residue was dissolved in Et2O
(200 mL) and washed with aqueous 1 M KHSO4 (200 mL). The
aqueous layer was extracted with Et2O (70 mL) and combined
organic layers were washed with aqueous 1 M LiCl (2 × 50 mL)
for eﬃcient DMF removal, dried over MgSO4, filtered, and
Et2O was removed under reduced pressure. The crude product
was purified by column chromatography (n-hexane/EtOAc 8/2
to n-hexane/EtOAc 1/1). Compound 3 (0.5 g, 30%) was obtained
as a yellowish amorphous solid. Rf = 0.55 (n-hexane/EtOAc 6/4).
1H-NMR (400 MHz, CDCl3): δ = 0.61 (q, J = 7.9 Hz, 6H), 1.00 (t,
J = 7.9 Hz, 9H), 1.08 (m, 21H), 2.44 (t, J = 2.4 Hz, 1H), 3.53 (d,
J = 13.8 Hz, 3H), 3.82 (s, 9H), 3.85–3.91 (m, 6H), 4.11–4.20 (m,
6H), 4.25 (d, J = 2.4 Hz, 2H), 4.27 (s, 2H), 4.29 (s, 2H), 4.73 (d,
J = 13.8 Hz, 3H), 6.83 (s, 3H), 6.93 (s, 3H). 13C-NMR (100 MHz,
CDCl3): δ = 4.3, 7.4, 11.2, 18.6, 36.5, 56.4, 58.5, 59.3, 68.1, 68.2,
68.4, 69.1, 74.7, 79.6, 87.8, 102.5, 103.2, 114.0, 114.1, 114.2,
116.7, 116.8, 131.9, 132.9, 133.0, 146.9, 147.0, 148.6, 148.7.
HRMS-ESI: m/z calcd for C54H76NaO9Si2 [M + Na]
+, 947.4920;
found, 947.4915. Compound 5, a side product, (0.9 g, 57%)
was obtained as a yellow amorphous solid. Rf = 0.32 (n-hexane/
EtOAc 6/4). 1H-NMR (400 MHz, CDCl3): δ = 1.07 (s, 21H), 2.44
(t, J = 2.4 Hz, 2H), 3.53 (d, J = 13.9 Hz, 3H), 3.83 (s, 9H),
3.86–3.90 (m, 6H), 4.11–4.20 (m, 6H), 4.24 (d, J = 2.4 Hz, 4H),
4.28 (s, 2H), 4.73 (d, J = 13.8 Hz, 3H), 6.82 (s, 3H), 6.91 (s, 3H).
13C-NMR (100 MHz, CDCl3): δ = 11.2, 18.6, 36.5, 56.4, 58.5,
59.3, 68.1, 68.4, 69.1, 74.7, 79.6, 87.8, 103.2, 114.0, 114.1,
116.8, 131.9, 132.9, 133.0, 146.9, 147.0, 148.7. HRMS-ESI: m/z
calcd for C48H62NaO9Si [M + Na]
+, 833.4055; found, 833.4027.
Propargyl-DEG-OH 7b. Compound 7b was prepared accord-
ing to a literature procedure.21 Anhydrous diethylene glycol 6b
(8.54 mL, 90.0 mmol) was added to the solution of t-BuOK
(5.10 g, 44.5 mmol) in dry THF (125 mL) at 0 °C which led to
the formation of a white precipitate. Next, the reaction mixture
was allowed to warm to RT and after 30 min of stirring a solu-
tion of propargyl bromide (4.85 mL (45.0 mmol) of a 80 wt%
solution in toluene) in dry THF (25 mL) was added dropwise
and the reaction mixture was stirred for 16 h under nitrogen
atmosphere. Next, the precipitate was removed by filtering over
Celite®, washed with THF and the filtrate was concentrated
under reduced pressure. The obtained residue was purified by
column chromatography (n-hexane/EtOAc 1/1 to EtOAc).
Compound 7b (5.3 g, 83%) was obtained as a yellow oil. Rf =
0.57 (EtOAc). 1H-NMR (400 MHz, CDCl3): δ = 2.43 (t, J = 2.3 Hz,
1H), 2.77 (br s, 1H), 3.56 (t, J = 4.6 Hz, 2H), 3.63–3.71 (m, 6H),
4.18 (d, J = 2.3 Hz, 2H). 13C-NMR (100 MHz, CDCl3): δ = 58.4,
61.7, 69.1, 70.2, 72.6, 74.8, 79.5. HRMS-ESI: m/z calcd for
C7H12NaO3 [M + Na]
+, 167.0679; found, 167.0678. The charac-
terisation of this compound has also been previously
reported.21
O-THP-propargyl-DEG 8b. Compound 8b was prepared
according to a literature procedure.16 To a solution of com-
pound 7b (3.75 g, 26.0 mmol) in dry CH2Cl2 (26 mL), DHP
(2.50 mL, 27.3 mmol) was added and the reaction mixture was
cooled to 0 °C. Next, p-TsOH·H2O (50.0 mg, 0.30 mmol) was
added to the reaction mixture which was then allowed to warm
to RT and stirred for 4 h during which additional DHP
(0.20 mL, 2.20 mmol) was added. Then, the reaction mixture
was washed with aqueous saturated NaHCO3 (40 mL), the
aqueous phase was extracted with CH2Cl2 (20 mL) and com-
bined organic layers were dried over MgSO4, filtered, and
CH2Cl2 was removed under reduced pressure. The crude
product was purified by column chromatography (n-hexane/
EtOAc 9/1 to n-hexane/EtOAc 7/3). Compound 8b (5.4 g, 90%)
was obtained as a yellow oil. Rf = 0.68 (n-hexane/EtOAc 1/1).
1H-NMR (400 MHz, CDCl3): δ = 1.48–1.63 (m, 4H), 1.68–1.86
(m, 2H), 2.42 (t, J = 2.4 Hz, 1H), 3.47–3.52 (m, 1H), 3.59–3.64
(m, 1H), 3.67–3.70 (m, 6H), 3.84–3.89 (m, 2H), 4.21 (d, J =
2.4 Hz, 2H), 4.62–4.64 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ =
19.6, 25.6, 30.7, 58.6, 62.4, 66.8, 69.3, 70.6, 70.7, 74.6,
79.8, 99.1. HRMS-ESI: m/z calcd for C12H20NaO4 [M + Na]
+,
251.1254; found, 251.1248.
O-THP-(TES)propargyl-DEG 9b. Compound 9b was prepared
according to a modified literature procedure.18 A solution of
compound 8b (1.50 g, 6.57 mmol) in dry THF (18 mL) was
cooled to −78 °C (solid CO2/acetone). Next, n-BuLi (4.70 mL,
7.56 mmol, 1.6 M in hexanes) was added dropwise and the
reaction mixture was stirred under nitrogen atmosphere at
−78 °C for 1 h before TES-Cl (1.38 mL, 8.21 mmol) was added.
The reaction mixture was then allowed to warm up to RT and
stirred under nitrogen atmosphere for additional 5 h before it
was quenched by addition of an aqueous saturated NH4Cl
solution (20 mL). Subsequently, the reaction mixture was
Paper Organic & Biomolecular Chemistry
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extracted with Et2O (2 × 25 mL) and the combined organic
layers were dried over MgSO4, filtered, and solvents were
removed under reduced pressure with the water bath kept at
RT (19 °C–21 °C). The crude product was purified by column
chromatography using (n-hexane/Et2O 9/1 to n-hexane/Et2O
7/3). Compound 9b (2.0 g, 91%) was obtained as a yellow oil.
Rf = 0.69 (n-hexane/EtOAc 7/3).
1H-NMR (400 MHz, CDCl3): δ =
0.60 (q, J = 8.0 Hz, 6H), 0.97 (t, J = 8.0 Hz, 9H), 1.47–1.63 (m,
4H), 1.67–1.86 (m, 2H), 3.46–3.52 (m, 1H), 3.58–3.63 (m, 1H),
3.66–3.70 (m, 6H), 3.83–3.88 (m, 2H), 4.22 (s, 2H), 4.62 (t, J =
3.7 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 4.4, 7.5, 19.6,
25.6, 30.7, 59.3, 62.3, 66.8, 69.0, 70.6, 70.7, 88.9, 99.1, 102.7.
HRMS-ESI: m/z calcd for C18H34NaO4Si [M + Na]
+, 365.2119;
found, 365.2103.
O-THP-(TIPS)propargyl-DEG 10b. Compound 10b was pre-
pared according to a modified literature procedure.18 A solu-
tion of compound 8b (1.50 g, 6.57 mmol) in dry THF (18 mL)
was cooled to −78 °C (solid CO2/acetone). Next, n-BuLi
(2.76 mL, 6.90 mmol, 2.5 M in hexanes) was added dropwise
and the reaction mixture was stirred under nitrogen atmo-
sphere at −78 °C for 1 h before TIPS-Cl (1.54 mL, 7.23 mmol)
was added. Then the procedure described for compound 9b
was followed. The crude product was purified by column
chromatography (n-hexane/Et2O, 95/5 to n-hexane/Et2O 8/2).
Compound 10b (1.9 g, 75%) was obtained as a yellowish oil.
Rf = 0.73 (n-hexane/EtOAc 7/3).
1H-NMR (400 MHz, CDCl3): δ =
1.06 (m, 21H), 1.48–1.64 (m, 4H), 1.68–1.86 (m, 2H), 3.46–3.52
(m, 1H), 3.58–3.63 (m, 1H), 3.67–3.73 (m, 6H), 3.84–3.89 (m,
2H), 4.24 (s, 2H), 4.63 (t, J = 3.7 Hz, 1H). 13C-NMR (100 MHz,
CDCl3): δ = 11.3, 18.7, 19.6, 25.6, 30.7, 59.3, 62.3, 66.7, 68.8,
70.6, 70.7, 87.7, 99.1, 103.4. HRMS-ESI: m/z calcd for
C21H40NaO4Si [M + Na]
+, 407.2588; found, 407.2569.
(TES)propargyl-DEG bromide 11b. Compound 11b was pre-
pared according to a modified literature procedure.18 Br2
(300 μL, 5.84 mmol) was added dropwise at 0 °C to a solution
of Ph3P (1.61 g, 6.13 mmol) in dry CH2Cl2 (23 mL) and the
solution was stirred under nitrogen atmosphere for 30 min
during which a white precipitate was formed. Next, solution of
compound 9b (2.00 g, 5.84 mmol) in dry CH2Cl2 (5 mL) was
added dropwise and the reaction mixture was stirred under
nitrogen atmosphere at 0 °C for additional 5 h during which
the white precipitate dissolved. Next, the reaction mixture was
diluted with CH2Cl2 (20 mL), water (20 mL) and then extracted
with CH2Cl2 (2 × 20 mL). The combined organic layers were
washed with aqueous saturated NaHCO3 (20 mL), dried over
MgSO4, filtered, and CH2Cl2 was removed under reduced
pressure with water bath kept at RT (19 °C–21 °C). The crude
product was purified by column chromatography (n-hexane/
Et2O 95/5 to n-hexane/Et2O 9/1). Compound 11b (1.6 g 84%)
was obtained as a pale yellow oil. Rf = 0.27 (n-hexane/Et2O 9/1).
1H-NMR (400 MHz, CDCl3): δ = 0.60 (q, J = 8.0 Hz, 6H), 0.98
(t, J = 8.0 Hz, 9H), 3.47 (t, J = 6.4 Hz, 2H), 3.68–3.73 (m, 4H),
3.81 (t, J = 6.4 Hz, 2H), 4.23 (s, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 4.4, 7.5, 30.3, 59.4, 68.9, 70.5, 71.3, 89.2, 102.5.
HRMS-ESI: m/z calcd for C13H25NaO2Si
79Br [M + Na]+,
343.0699; found, 343.0685.
(TIPS)propargyl-DEG bromide 12b. Compound 12b was pre-
pared according to a modified literature procedure.18 Br2
(250 μL, 4.86 mmol) was added dropwise at 0 °C to a solution
of Ph3P (1.34 g, 5.11 mmol) in dry CH2Cl2 (20 mL) and the
solution was stirred under nitrogen atmosphere for 30 min
during which a white precipitate was formed. Next, solution of
compound 10b (1.87 g, 4.86 mmol) in dry CH2Cl2 (8 mL) was
added dropwise and then the procedure described for com-
pound 11b was followed. The crude product was purified by
column chromatography (n-hexane/Et2O 95/5 to n-hexane/Et2O
9/1). Compound 12b (1.7 g, 93%) was obtained as a colourless
oil. Rf = 0.29 (n-hexane/Et2O 9/1).
1H-NMR (400 MHz, CDCl3):
δ = 1.06 (m, 21H), 3.47 (t, J = 6.4 Hz, 2H), 3.69–3.74 (m, 4H),
3.81 (t, J = 6.4 Hz, 2H), 4.25 (s, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 11.2, 18.7, 30.3, 59.3, 68.8, 70.5, 71.3, 87.9, 103.2.
HRMS-ESI: m/z calcd for C16H31NaO2Si
79Br [M + Na]+,
385.1169; found, 385.1155.
Propargyl-DEG bromide 13b. Compound 13b was prepared
according to a modified literature procedure.18 Br2 (260 μL,
5.04 mmol) was added dropwise at 0 °C to a solution of Ph3P
(1.37 g, 5.25 mmol) in dry CH2Cl2 (22 mL) and the solution
was stirred under nitrogen atmosphere for 30 min during
which a white precipitate was formed. Next, solution of com-
pound 8b (1.14 g, 4.99 mmol) in dry CH2Cl2 (2 mL) was added
dropwise and then the procedure described for compound 11b
was followed. The crude product was purified by column
chromatography (n-hexane/Et2O 1/2). Compound 13b (1.0 g,
91%) was obtained as a colourless oil. Rf = 0.12 (n-hexane/
EtOAc 95/5). 1H-NMR (400 MHz, CDCl3): δ = 2.44 (t, J = 2.4 Hz,
1H), 3.49 (t, J = 6.3 Hz, 2H), 3.69–3.74 (m, 4H), 3.82 (t, J = 6.3 Hz,
2H), 4.22 (d, J = 2.4 Hz, 2H). 13C-NMR (100 MHz, CDCl3):
δ = 30.4, 58.6, 69.2, 70.5, 71.4, 74.8, 79.7. HRMS-ESI: m/z calcd for
C7H11NaO2
79Br [M + Na]+, 228.9835; found, 228.9839.
Di(O-THP)-O-DEG-propargyl CTV 15b. To a solution of
diTHP protected CTV scaﬀold 14 (1.50 g, 2.60 mmol) in aceto-
nitrile (12 mL) Cs2CO3 (1.02 g, 3.12 mmol) was added, followed
by the addition of a solution of alkyne bromide 13b (700 mg,
3.38 mmol) in acetonitrile (1 mL) and the resulting reaction
mixture was stirred for 15 h. Afterwards, the reaction mixture
was concentrated under reduced pressure and the residue was
diluted with EtOAc (150 mL) and washed with aqueous 1 M
KHSO4 (150 mL). Aqueous layer was extracted with EtOAc
(50 mL) and combined organic layers were washed with brine
(100 mL), dried over MgSO4, filtered, and EtOAc was removed
under reduced pressure. The crude product was purified by
column chromatography (n-hexane/EtOAc 7/3 to n-hexane/
EtOAc 1/1). Compound 15b (1.5 g, 83%) was obtained as a
white foam. Rf = 0.29 (n-hexane/EtOAc 1/1).
1H-NMR (500 MHz,
CDCl3): δ = 1.51–1.76 (m, 6H), 1.80–2.07 (m, 6H), 2.45 (t, J =
2.4 Hz, 1H), 3.49–3.60 (m, 5H), 3.70–3.76 (m, 4H), 3.81–3.87
(m, 12H), 4.00–4.06 (m, 1H), 4.10–4.22 (m, 4H), 4.70–4.74 (m,
3H), 5.19–5.22 (m, 1H), 5.41–5.43 (m, 1H), 6.84–6.86 (m, 3H),
6.90–6.92 (m, 1H), 7.13–7.17 (m, 2H). 13C-NMR (125 MHz,
CDCl3): δ = 18.7, 19.0, 25.3, 30.4, 30.5, 36.3, 36.4, 36.5, 55.9, 56.0,
56.1, 56.2, 56.4, 56.5, 56.7, 58.4, 61.9, 62.2, 69.0, 69.2, 69.7, 70.6,
74.6, 79.7, 97.1, 98.2, 98.3, 113.5, 113.7, 113.8, 114.0, 114.2,
Organic & Biomolecular Chemistry Paper
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114.3, 114.5, 116.1, 116.3, 118.5, 118.6, 118.8, 118.9, 119.6, 119.8,
119.9, 120.0, 131.4, 131.6, 131.7, 131.8, 131.9, 132.1, 132.2, 133.0,
133.1, 133.2, 133.8, 133.9, 144.9, 145.0, 145.1, 145.2, 146.6, 146.7,
148.4, 148.5, 149.0. HRMS-ESI: m/z calcd for C41H50NaO10
[M + Na]+, 725.3296; found, 725.3273.
O-DEG-propargyl CTV-diOH 16b. To a solution of compound
15b (1.47 g, 2.09 mmol) in MeOH (40 mL), 1 M HCl (2 mL) was
added dropwise which resulted in the formation of a precipi-
tate. The reaction mixture was stirred for 2.5 h during which
the suspension turned into a yellow solution. Afterwards,
MeOH was removed under reduced pressure and the solid
residue was dissolved in CHCl3 (60 mL) and washed with water
(50 mL). Next, the aqueous phase was extracted with CHCl3
(2 × 30 mL) and the combined organic layers were dried over
MgSO4, filtered, and CHCl3 was removed under reduced
pressure. The crude product was purified by column chromato-
graphy (CHCl3 to CHCl3/MeOH 25/1). Compound 16b (1.1 g,
100%) was obtained as a white foam. Rf = 0.33 (n-hexane/
EtOAc 3/7). 1H-NMR (500 MHz, CDCl3): δ = 2.45 (t, J = 2.4 Hz,
1H), 3.45–3.49 (m, 3H), 3.69–3.74 (m, 4H), 3.78 (s, 3H),
3.80–3.87 (m, 8H), 4.09–4.13 (m, 1H), 4.15–4.24 (m, 3H),
4.64–4.70 (m, 3H), 5.62 (m, 1H), 5.65 (m, 1H), 6.77 (s, 1H), 6.77
(s, 1H), 6.82 (s, 1H), 6.87–6.91 (m, 3H). 13C-NMR (125 MHz,
CDCl3): δ = 36.2, 36.4, 56.0, 56.2, 58.4, 69.0, 69.1, 69.7, 70.6,
74.7, 79.7, 112.3, 113.8, 115.6, 115.7, 116.3, 131.2, 131.3, 131.9,
132.3, 132.6, 132.9, 144.2, 145.3, 146.8, 148.5. HRMS-ESI: m/z
calcd for C31H34NaO8 [M + Na]
+, 557.2164; found, 557.2133.
O-DEG-propargyl-O-DEG-(TIPS)propargyl CTV-OH 17b. To
the solution of compound 16b (845 mg, 1.58 mmol) in DMF
(20 mL) Cs2CO3 (567 mg, 1.74 mmol) was added, followed by
the addition of the solution of TIPS-protected alkyne bromide
12b (603 mg, 1.66 mmol) in DMF (4 mL) and the resulting
reaction mixture was stirred for 28 h during which additional
Cs2CO3 (520 mg, 1.60 mmol) was added in order to improve
the conversion. Then, DMF was removed under reduced
pressure and the viscous residue was dissolved in EtOAc
(100 mL) and washed with aqueous 1 M KHSO4 (150 mL).
Next, the aqueous phase was extracted with EtOAc (50 mL) and
the combined organic layers were dried over MgSO4, filtered,
and EtOAc was removed under reduced pressure. The crude
product was purified by column chromatography (n-hexane/
EtOAc 7/3 to n-hexane/EtOAc 3/7). Compound 17b (470 mg,
36%) was obtained as a yellow gum. Rf = 0.59 (n-hexane/EtOAc
3/7). 1H-NMR (500 MHz, CDCl3): δ = 1.07 (m, 21H), 2.43 (dd,
J = 2.4 Hz, 4.4 Hz, 1H), 3.49–3.51 (d, J = 13.8 Hz, 3H), 3.67–3.70
(m, 2H), 3.71–3.75 (m, 6H), 3.82 (s, 6H), 3.83–3.87 (m, 7H),
4.09–4.19 (m, 6H), 4.25 (d, J = 1.4 Hz, 2H), 4.66–4.75 (m, 3H),
5.50 (m, 1H), 6.80 (m, 1H), 6.80–6.83 (m, 2H), 6.88–6.91 (m,
3H). 13C-NMR (125 MHz, CDCl3): δ = 11.2, 18.6, 36.3, 36.5,
56.2, 56.4, 58.5, 59.2, 68.8, 69.0, 69.2, 69.7, 69.8, 70.7, 74.7,
79.7, 87.8, 103.3, 112.3, 113.9, 114.0, 115.7, 116.2, 116.4, 116.5,
131.3, 131.8, 132.1, 132.5, 132.8, 132.9, 144.3, 145.4, 146.9,
147.0, 148.6. HRMS-ESI: m/z calcd for C47H64NaO12Si
[M + Na]+, 839.4161; found, 839.4128. Compound 18b, a side
product, (350 mg, 20%) was obtained as a yellow syrup. Rf =
0.74 (n-hexane/EtOAc 3/7). 1H-NMR (500 MHz, CDCl3): δ = 1.06
(m, 42H), 2.41 (t, J = 2.4 Hz, 1H), 3.52 (d, J = 13.8 Hz, 3H),
3.67–3.70 (m, 2H), 3.71–3.75 (m, 10H), 3.79–3.87 (m, 15H),
4.07–4.19 (m, 8H), 4.24 (s, 4H), 4.72 (d, J = 13.8 Hz, 3H),
6.80–6.82 (m, 3H), 6.88–6.90 (m, 3H). 13C-NMR (125 MHz,
CDCl3): δ = 11.2, 18.7, 36.6, 56.4, 58.5, 59.2, 68.8, 69.0, 69.2,
69.7, 69.8, 70.7, 74.7, 79.7, 87.8, 103.3, 114.0, 116.3, 116.4,
131.9, 132.8, 147.0, 147.1, 148.6. HRMS-ESI: m/z calcd for
C63H94NaO12Si2 [M + Na]
+, 1121.6176; found, 1121.6140.
Starting material 16b (210 mg, 25%) was recovered.
O-DEG-propargyl-O-DEG-(TIPS)propargyl-O-DEG-(TES)pro-
pargyl CTV 4. To the solution of compound 17b (400 mg,
490 μmol) in dry DMF (7 mL) Cs2CO3 (210 mg, 636 μmol) was
added, followed by the addition of the solution of TES-pro-
tected alkyne bromide 11b (240 mg, 734 μmol) in dry DMF
(1 mL) and the resulting reaction mixture was stirred under
nitrogen atmosphere for 7 h during which additional Cs2CO3
(160 mg, 491 μmol) and the solution of compound 11b
(160 mg, 498 μmol) in dry DMF (0.8 mL) was added in order to
improve the conversion. Afterwards, DMF was removed under
reduced pressure and the viscous residue was dissolved in
EtOAc (70 mL) and washed with aqueous 1 M KHSO4 (60 mL).
The aqueous layer was extracted with EtOAc (50 mL) and com-
bined organic layers were washed with aqueous 1 M LiCl
(55 mL) for eﬃcient DMF removal. The aqueous LiCl phase
was extracted with EtOAc (20 mL) and the organic layer was
combined with the previous one, dried over MgSO4, filtered,
and EtOAc was removed under reduced pressure. The crude
product was purified by column chromatography (CH2Cl2 to
CH2Cl2/MeOH 100/1). Compound 4 (320 mg, 62%) was
obtained as a yellow syrup. Rf = 0.27 (n-hexane/EtOAc 1/1).
1H-NMR (500 MHz, CDCl3): δ = 0.58 (q, J = 7.9 Hz, 6H), 0.98 (t,
J = 7.9 Hz, 9H), 1.06 (m, 21H), 2.42 (t, J = 2.4 Hz, 1H), 3.51 (d,
J = 13.9 Hz, 3H), 3.66–3.75 (m, 12H), 3.79–3.87 (m, 15H),
4.08–4.19 (m, 8H), 4.22 (s, 2H), 4.24 (s, 2H), 4.72 (d, J = 13.8 Hz,
3H), 6.82 (s, 3H), 6.89 (s, 3H). 13C-NMR (125 MHz, CDCl3):
δ = 3.3, 6.5, 10.2, 17.6, 35.5, 55.4, 57.5, 58.2, 67.8, 67.9, 68.0,
68.2, 68.7, 68.8, 69.7, 73.6, 78.7, 86.7, 88.0, 101.6, 102.3, 113.0,
115.3, 115.4, 130.9, 131.8, 146.0, 147.5. HRMS-ESI: m/z calcd
for C60H88NaO12Si2 [M + Na]
+, 1079.5707; found, 1079.5671.
Tri-O-propargyl CTV 20. TBAF·3H2O (78.9 mg, 250 μmol) was
added to a solution of compound 19 (83.5 mg, 100 μmol) in
dry CH2Cl2 (0.5 mL) and the resulting solution, which quickly
turned into a suspension, was stirred for 4 h. The suspension
was then diluted with CH2Cl2 (2.5 mL) and CHCl3 (2.0 mL)
and gently heated to ca. 40 °C to dissolve the precipitate. The
organic phase was then washed with brine (5.0 mL) and the
resulting aqueous phase was extracted with CHCl3 (3.0 mL).
The combined organic layers were dried over MgSO4, filtered,
and solvents were removed under reduced pressure. The crude
product was purified by column chromatography (CH2Cl2 to
CH2Cl2/MeOH 50/1). Compound 20 (49 mg, 94%) was obtained
as a white solid. Rf = 0.82 (petroleum ether/EtOAc 1/1).
1H-NMR (400 MHz, CDCl3): δ = 2.46 (t, J = 2.4 Hz, 3H), 3.57 (d,
J = 13.8 Hz, 3H), 3.85 (s, 9H), 4.72 (d, J = 2.4 Hz, 6H), 4.77 (d,
J = 13.8 Hz, 3H), 6.88 (s, 3H), 7.02 (s, 3H). 13C-NMR (100 MHz,
CDCl3): δ = 36.5, 56.2, 57.0, 75.7, 79.0, 113.9, 116.5, 131.6,
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133.4, 145.5, 148.4. HRMS-ESI: m/z calcd for C33H30NaO6
[M + Na]+, 545.1935; found, 545.1935. The characterisation of
this compound has also been previously reported.2
Tri-O-MEG-propargyl CTV 21. TBAF·3H2O (47.3 mg,
150 μmol) was added to a solution of compound 5 (81.1 mg,
100 μmol) in dry CH2Cl2 (0.5 mL) and the resulting solution
was stirred for 1 h. The solution was then diluted with CH2Cl2
(4.5 mL), washed with brine (5.0 mL) and aqueous phase was
extracted with CH2Cl2 (3.0 mL). The combined organic layers
were dried over MgSO4, filtered, and CH2Cl2 was removed
under reduced pressure. The crude product was purified by
column chromatography (CH2Cl2 to CH2Cl2/MeOH 100/1).
Compound 21 (56 mg, 85%) was obtained as a white foam.
Rf = 0.61 (petroleum ether/EtOAc 1/1).
1H-NMR (400 MHz,
CDCl3): δ = 2.42–2.46 (m, 3H), 3.51 (d, J = 13.8 Hz, 3H), 3.82 (s,
9H), 3.84–3.88 (m, 6H), 4.10–4.19 (m, 6H), 4.22–4.26 (m, 6H),
4.71 (d, J = 13.8 Hz, 3H), 6.81 (s, 3H), 6.90 (s, 3H). 13C-NMR
(100 MHz, CDCl3): δ = 36.5, 56.3, 58.5, 68.3, 69.0, 74.7, 79.6,
114.0, 116.8, 131.9, 133.0, 146.9, 148.6. HRMS-ESI: m/z calcd
for C39H42NaO9 [M + Na]
+, 677.2721; found, 677.2701.
Tri-O-DEG-propargyl CTV 22. TBAF·3H2O (78.9 mg,
250 μmol) was added to the solution of compound 18b
(110.0 mg, 100 μmol) in dry CH2Cl2 (0.5 mL) and the resulting
solution was stirred for 1 h. Then the procedure described for
compound 21 was followed. The crude product was purified by
column chromatography (CH2Cl2 to CH2Cl2/MeOH 100/1).
Compound 22 (59 mg, 75%) was obtained as a pale yellow
amorphous solid. Rf = 0.11 (petroleum ether/EtOAc 1/1).
1H-NMR (400 MHz, CDCl3): δ = 2.43 (m, 3H), 3.52 (d, J =
13.7 Hz, 3H), 3.65–3.77 (m, 12H), 3.79–3.88 (m, 15H),
4.08–4.21 (m, 12H), 4.73 (d, J = 13.8 Hz, 3H), 6.82 (s, 3H), 6.90
(s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 36.5, 56.3, 58.4, 69.0,
69.1, 69.7, 70.6, 74.6, 79.7, 114.0, 116.4, 131.9, 132.8, 147.0,
148.5. HRMS-ESI: m/z calcd for C45H54NaO12 [M + Na]
+,
809.3507; found, 809.3496.
Peptide synthesis and Cu(I)catalyzed azide–alkyne
cycloaddition chemistry
Synthesis of linear peptides 23–26. General method for auto-
mated peptide synthesis: the peptides were synthesized on a
PTI Tribute-UV peptide synthesizer. Tentagel S RAM resin
(1.0 g, 0.25 mmol, 1.0 equiv. or 400 mg, 0.1 mmol, 1.0 equiv.)
was allowed to swell (3 × 10 min). Removal of the Fmoc group
was achieved by treatment of the resin with 20% piperidine in
DMF using the RV_top_UV_Xtend protocol from the Tribute-
UV peptide synthesizer followed by a DMF washing step (5 ×
30 s). The Fmoc-protected amino acids (on a 0.1 mmol scale
5 eq. of Fmoc amino acids were used and on a 0.25 mmol scale
4 eq. of Fmoc amino acids were used) were coupled using
HCTU (5 eq. or 4 eq. respectively) and DiPEA (10 eq. or 8 eq.
respectively) in DMF, with 2 min pre-activation. The coupling
time was 10 min when the peptide was synthesized on a
0.1 mmol scale and 20 min when the 0.25 mmol scale was con-
ducted. After every coupling the resin was washed with DMF
(6 × 30 s). After coupling of the last amino acid, the Fmoc
group was cleaved using the deprotection conditions described
above and the resulting free N-terminus was acetylated by
treatment of the resin bound peptide with acetic anhydride
(250 μL) and DiPEA (eq. as above) in DMF using the standard
coupling times (as above). After the last step the resin was
washed with DMF (5 × 30 s), CH2Cl2 (5 × 30 s), dried by nitro-
gen flow for 10 min, followed by cleavage of the resin-bounded
peptide. Cleavage and global deprotection was achieved by
treatment of the resin with TFA/H2O/TIS/EDT (10 mL for the
0.25 mmol scale and 5 mL for the 0.1 mmol scale, 90/5/2.5/2.5,
v/v/v/v) for 3 hours. Next, the peptide was precipitated by drop-
wise addition of the TFA mixture to a cold (4 °C) solution of
MTBE/n-hexane (1/1, 90 mL for the 0.25 mmol scale and
45 mL for the 0.1 mmol scale). After centrifugation (3500 rpm
for 5 min) the supernatant was decanted and the pellet was re-
suspended in MTBE/n-hexane (volumes as above) and the
above procedure was repeated twice. Finally, the pellet was dis-
solved in t-BuOH/H2O (1/1, v/v) and lyophilized to yield the
crude linear peptides. The following peptides were
synthesized:
Linear peptide 23, Ac-CNYYGSNC-NH2, tR = 13.9 min.
LCMS-ESI: average mass calcd [M]+: 964.0; found: 964.3.
Analytical data of linear peptides 24–26 were identical to
those described previously.4
Peptide cyclisation – CDR mimics 28–31. All linear peptides
were cyclized at a concentration of 1 mM in the following way.
The crude linear peptide and the perhydrotriazine hinge 27
were weighed into a round bottom flask (250 mL or 500 mL).
Then, acetonitrile was added followed by the addition of
aqueous solution of NH4HCO3 (20 mM, pH 7.9) to obtain a 1/3
(acetonitrile/NH4HCO3-solution v/v) mixture. Progress of the
cyclization was monitored by analytical HPLC after 30 min. For
all peptides, 30 min were suﬃcient for the complete cycliza-
tion. Next, acetonitrile was removed under reduced pressure
and the remaining aqueous solution/suspension was lyophi-
lized. The crude cyclic peptides were purified using (semi)pre-
parative reverse phase HPLC. The fractions containing product
were pooled and lyophilized yielding the desired cyclic pep-
tides as white fluﬀy solids.
Cyclic peptide 28, purified using 0% to 40% of
buﬀer B in buﬀer A. Overall yield: 14% (19 steps, average yield
90% per step). tR = 14.5 min. LCMS-ESI: average mass calcd
[M]+: 1214.3; found: 1214.3.
Purification and analytical data of cyclic peptides (CDR
mimics) 29–31 were described previously.4
Preparation of synthetic antibodies 35–40 and 44–49
General procedure for the synthesis of synthetic antibodies
35–40. Scaﬀold 2 or 3 or 4 (5.2 mg or 6.0 mg or 6.9 mg, respect-
ively, 6.50 μmol), CDR mimic 31 (10.3 mg, 6.50 μmol), TBTA
(1.0 mg, 1.95 μmol) were dissolved in degassed DMF (975 μL)
and the resulting solution was kept under nitrogen atmo-
sphere in a 5 mL round bottom flask. Then the solution was
diluted with degassed i-PrOH (1300 μL) and deionised H2O
(290 μL) before freshly prepared 0.2 M aqueous sodium ascor-
bate (19.5 μL, 3.90 μmol) and 0.12 M aqueous CuSO4 (16.3 μL,
1.95 μmol) were added in the given order. After 1 h and
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15 min of stirring, AgNO3 (6.1 mg, 35.75 μmol) was added to
the reaction mixture which was stirred for another 2 h.
Following this treatment with AgNO3, another portion of TBTA
(1.0 mg, 1.95 μmol) and CDR mimic 30 (9.1 mg, 6.50 μmol)
were added to the reaction mixture, followed by the addition of
0.2 M aqueous sodium ascorbate (29.0 μL, 5.85 μmol) and 0.12
M aqueous CuSO4 (16.3 μL, 1.95 μmol). The reaction mixture
was stirred for 3 h and after two hours of stirring freshly pre-
pared 0.2 M aqueous aminoguanidine hydrochloride (59.0 μL,
11.70 μmol) and additional 0.2 M aqueous sodium ascorbate
(10.0 μL, 1.95 μmol) were added. Then, 1 M solution of
TBAF·3H2O in THF (114 μL, 113.75 μmol) was added and the
resulting suspension was stirred overnight (i.e. 18 h). This was
followed by addition of TBTA (1.4 mg, 2.60 μmol) to the reac-
tion mixture which was then stirred for 45 min before being
briefly sonicated and split into two halves. Next, a solution of
CDR mimic 29 (5.6 mg, 3.90 μmol) in degassed DMF (150 μL)
was added to one half of the reaction mixture while a solution
of CDR mimic 28 (4.7 mg, 3.90 μmol) in degassed DMF
(250 μL) was added to the other half. In addition, freshly pre-
pared 0.2 M aqueous sodium ascorbate (39.0 μL, 7.80 μmol),
0.12 M aqueous CuSO4 (10.9 μL, 1.30 μmol) and freshly pre-
pared 0.2 M aqueous aminoguanidine hydrochloride (39.0 μL,
7.80 μmol) were added to both reaction mixtures which were
then stirred for 2.5 h during which, after 1.5 h of stirring,
additional 0.2 M aqueous sodium ascorbate (19.5 μL,
3.90 μmol) and 0.2 M aqueous aminoguanidine hydrochloride
(39.0 μL, 7.80 μmol) were added. Then, the solvents
were removed under stream of nitrogen (for ca. 1.5 h) and the
resulting viscous residue (usually around 50 μL) was diluted
with HPLC buﬀer A (350 μL) and HPLC buﬀer B (150 μL),
sonicated, centrifuged (13 000g for 6 min) and the product in
the supernatant was purified by semi-preparative reverse
phase HPLC using a gradient of 27% to 37% of buﬀer B in
buﬀer A. Fractions containing the product were pooled and
lyophilised. In the majority of the experiments, significant
amounts (89% on average) of desired synthetic antibodies
were obtained in purities of 91%–96% along with smaller
portion of impure fractions which were re-purified using the
same gradient.
General procedure for the synthesis of synthetic antibodies
44–49. The above described procedure was also used with the
following order of addition of CDR mimics. CDR mimic 29
(9.6 mg, 6.50 μmol) was introduced via CuAAC as the first and
the CDR mimic 28 (7.9 mg, 6.50 μmol) as the second onto the
either scaﬀold 2, 3, or 4. After the reaction mixture was split a
solution of CDR mimics 31 (6.2 mg, 3.90 μmol) in degassed
DMF (150 μL) was added to one half of the reaction mixture
while a solution of CDR mimic 30 (5.5 mg, 3.90 μmol) in
degassed DMF (150 μL) was added to the other half. Moreover,
for this particular sequence of addition of CDR mimics,
double amount 1 M solution of TBAF·3H2O in THF (228 μL,
227.5 μmol) had to be used for successful removal of TIPS pro-
tecting group.
Synthetic antibody 35 (2.8 mg, overall yield 17%, average
yield 70% per step, 5 steps) was obtained as a white
fluﬀy solid. tR = 17.1 min. LCMS-ESI: average mass calcd
[M + 3H]3+: 1472.3; found: 1472.0. MALDI: exact mass calcd
[M + H]+ 4411.7; found: 4411.1.
Synthetic antibody 36 (3.4 mg, overall yield 21%, average
yield 73% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.2 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1516.4; found: 1516.0. MALDI: exact mass calcd [M + H]+
4543.8; found: 4543.9.
Synthetic antibody 37 (2.6 mg, overall yield 15%, average
yield 69% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.3 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1560.4; found: 1560.2. MALDI: exact mass calcd [M + H]+
4675.9; found: 4675.6.
Synthetic antibody 38 (2.4 mg, overall yield 16%, average
yield 69% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.7 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1460.2; found: 1460.0. MALDI: exact mass calcd [M + H]+
4375.6; found: 4376.0.
Synthetic antibody 39 (2.6 mg, overall yield 17%, average
yield 70% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.7 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1504.3; found: 1504.0. MALDI: exact mass calcd [M + H]+
4507.6; found: 4507.5.
Synthetic antibody 40 (2.8 mg, overall yield 17%, average
yield 70% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.8 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1548.4; found: 1548.0. MALDI: exact mass calcd [M + H]+
4639.7; found: 4639.8.
Synthetic antibody 44 (2.7 mg, overall yield 18%, average
yield 71% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.2 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1425.2; found: 1424.9. MALDI: exact mass calcd [M + H]+
4270.6; found: 4270.9.
Synthetic antibody 45 (2.4 mg, overall yield 16%, average
yield 69% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.3 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1469.3; found: 1469.0. MALDI: exact mass calcd [M + H]+
4402.7; found: 4402.6.
Synthetic antibody 46 (2.5 mg, overall yield 16%, average
yield 69% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.3 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1513.3; found: 1513.0. MALDI: exact mass calcd [M + H]+
4534.7; found: 4534.5.
Synthetic antibody 47 (2.4 mg, overall yield 15%, average
yield 69% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.2 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1448.6; found: 1448.3. MALDI: exact mass calcd [M + H]+
4340.7; found: 4340.7.
Synthetic antibody 48 (2.0 mg, overall yield 13%, average
yield 66% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.3 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
1492.6; found: 1492.3. MALDI: exact mass calcd [M + H]+
4472.8; found: 4472.8.
Synthetic antibody 49 (1.9 mg, overall yield 12%, average
yield 65% per step, 5 steps) was obtained as a white fluﬀy
solid. tR = 17.3 min. LCMS-ESI: average mass calcd [M + 3H]
3+:
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1536.7; found: 1536.4. MALDI: exact mass calcd [M + H]+
4604.8; found: 4604.7.
Notes on the one-pot protocol. During optimization of the
above protocols the following observations turned out to be
crucial to the success of the preparation of the synthetic
antibodies.
1. Solvents had to be degassed prior to carrying out the
reaction sequence otherwise the CuAAC introduction of the
CDR mimics proceeded poorly. This was especially important
for introduction of the third CDR mimic else almost no con-
version was observed.
2. Using less than 5.5 equivalents of AgNO3 led, in some
cases, to incomplete TES removal within 2 h. However,
using more than 5.5 equivalents of AgNO3 (10 equivalents
at the maximum) slowed down the subsequent introduction
of the second CDR mimic although it did expedite TES
removal.
3. Addition of the least soluble CDR mimic (that is com-
pound 28 which did not fully dissolve in the chosen
solvent mixture) to a scaﬀold already bearing another CDR
mimic prevented the need for prolonged reaction times which
was not the case when the least soluble CDR mimic 28
was attached as the first mimic to either scaﬀold 2, 3 or 4. In
the latter case, the first CuAAC CDR mimic introduction
required up to 8 h for completion and subsequent reactions
usually required more time than described in the general
procedure.
4. In cases when CDR mimics 28 and 29 were attached onto
CTV scaﬀold derivatives 3 or 4, conversion of TIPS removal
decreased to ca. 60%–75%. However, close to complete conver-
sion could be achieved by increasing the amount of used
TBAF·3H2O in degassed THF from 17.5 to 35 equivalents.
5. Fresh portions of CuSO4, sodium ascorbate and TBTA
had to be added for every CuAAC introduction of CDR mimics
to scaﬀolds 2, 3 or 4 as well as its CDR mimic(s) containing
derivatives in order to secure good conversion. “Recycling” of
copper from the first CuAAC or alternatively from the first and
the second CuAAC by reducing the initially added CuSO4 with
additional sodium ascorbate for the subsequent CuAAC did
not lead to satisfactory conversions.
6. Extension of reaction times of CuAAC introduction of the
third CDR mimic beyond 2.5 h hardly improved the conversion
even when additional CuSO4, sodium ascorbate and TBTA were
added during the reaction. The reaction tended to stop and a
slow degradation of the product as well as formation of side
products were observed after ca. 4 h.
7. Formation of dehydroascorbic acid adducts of arginine
containing CDR mimics, which was mainly observed at the
very end of the synthesis when reaction mixture was concen-
trated under stream of nitrogen, could be eﬀectively prevented
by addition of aminoguanidine hydrochloride as a scavenger
of the formed dehydroascorbic acid.12
8. After evaluation of several gradients on C4, C8, and C18
reversed-phase columns, a gradient of 27% to 37% of buﬀer B
into buﬀer A on a C8 column was selected as the best one for
purification of all prepared synthetic antibodies.
Surface plasmon resonance experiments
The surface plasmon resonance experiments were performed
using Biacore™ X100 SPR biosensor (Biacore AB, Uppsala,
Sweden) equipped with CM5 sensor chip (Biacore AB, Uppsala,
Sweden). hTNFα (ca. 51 kDa = trimer, >97% pure based on
SDS-PAGE) was immobilised using amine-coupling chem-
istry.22 Surfaces of two flow cells were activated for 7 min with a
1 : 1 mixture of 0.1 M NHS (N-hydroxysuccineimide) and 0.4 M
EDC [3-(N,N-dimethylamino)propyl-N-ethylcarbodiimide] at a
flow rate of 5 μL min−1. hTNFα at a concentration of 30 μg mL−1
in 10 mM sodium acetate, pH 4.5, was immobilised at a density
of 984 RU and 1024 RU, representing two diﬀerent CM5 chips,
on flow cell 2. Flow cell 1 was left blank to serve as a reference
surface. Both surfaces were blocked with a 7 min injection of
1 M ethanolamine, pH 8.5, at a flow rate of 5 μL min−1. The
immobilisation was performed at 21 °C with MES running
buﬀer (10 mM MES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, pH
6.0) using Biacore immobilisation wizard with target density of
1600 RU. Following the immobilisation, non-covalently bound
oligomeric units of hTNFα were removed by injections of regen-
eration solution (5 mM NaOH, 150 mM NaCl, ca. 6 × 20 s).
The activity of immobilised hTNFα was verified with anti-
hTNFα specific monoclonal antibody (Life Technologies,
Thermo Fisher Scientific, clone 68B 2B3) in a single-cycle
experiment with 3-fold dilutions of the mAb (highest concen-
tration 100 nM) at a flow rate of 30 μL min−1 and a tempera-
ture of 21 °C. The experiment was performed using two
diﬀerent running buﬀers; the above mentioned MES buﬀer as
well as its DMSO supplemented version, MES-DMSO, (10 mM
MES, 150 mM NaCl, 3 mM EDTA, 0.05% P20, 5% DMSO, pH
6.0). Duration of the association/dissociation phase was set to
180 s and 420 s, respectively. The sensogram data were fitted
according to 1 : 1 binding model using Biacore X100
Evaluation software version 2.0.1 (Biacore AB, Uppsala,
Sweden). The anti-hTNFα specific mAb bound immobilised
hTNFα with KD of 15 nM and 32 nM in MES and MES-DMSO
buﬀer, respectively. Thus, a 2-fold decrease in aﬃnity for
experiments performed in MES-DMSO buﬀer was observed.
Solutions of synthetic antibodies were prepared at a concen-
tration of 16 μM by dissolution of the synthetic antibody in
DMSO (volume corresponding to 5% of the final volume) and
subsequent dropwise dilution with 1.05 × MES-DMSO
(10.5 mM MES, 157.5 mM NaCl, 3.15 mM EDTA, 0.0525% P20,
pH 6.0) aided by vigorous stirring by vortex. The aﬃnity of syn-
thetic antibodies towards hTNFα was screened at 2 μM and the
synthetic antibodies which showed binding were further tested
in a multi-cycle kinetic experiment at 8 μM with 2-fold
dilutions at a flow rate of 30 μL min−1 and a temperature of
21 °C in MES-DMSO buﬀer. Duration of the association/dis-
sociation phase was set to 120 s and 300 s, respectively.
Regeneration of the sensor surface was accomplished by a 12 s
injection of a regeneration solution (5 mM NaOH, 150 mM
NaCl) followed by a 300 s stabilisation period. Experiments
were performed in duplicate in two independent experiments
(n = 2) on chips with diﬀerent immobilisation level of hTNFα
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(984 RU and 1024 RU). The medium concentration (2 μM) was
injected twice as a control of stability of the experimental
setup. During data processing the highest tested concen-
tration, i.e. 8 μM was excluded from fitting as the obtained
curves had irregular shape. The blank subtracted and injection
peaks cleaned data were evaluated in Biacore X100 Evaluation
software version 2.0.1 (Biacore AB, Uppsala, Sweden) using
heterogeneous ligand fitting model. The heterogeneous fitting
model was used as three out of six lysine residues of hTNFα,
via which immobilisation happens, reside near the binding
site of infliximab and thus synthetic antibodies. Following
data evaluation, KD representing the binding event contribut-
ing the most to total Rmax was selected as the value best
describing the strength of the observed binding.
Modelling of the molecular constructs
Molecular models of CTV-derivatives, peptide loops and syn-
thetic antibody mimics were constructed using the Maestro
software (http://www.Schrödinger.com) interfaced with
MacroModel23 minimization and conformational analysis
options using the MMFFs and OPLS-2005 force fields, PRCG
minimization with water as a solvent. In short CDR loop
mimics were generated by construction of the peptides in the
grow mode, followed by introduction of the cyclization hinge 27
and minimization of obtained CDR peptide loops 28–31. Multi
conformer analysis options allowed obtaining CDR mimics
close to the global minimum energy conformations. The CDR
mimics were connected subsequently to the appropriate CTV
scaﬀold derivatives 2, 3 or 4 and minimized after each connec-
tion step. At this stage MD (Molecular Dynamics) studies were
omitted, since the primary goal was to obtain a visual insight as
a qualitative explanation of the observed results.
Aqueous solubility of CTV scaﬀold derivatives determination
Excess of scaﬀold derivatives 20, 21, and 22 (ca. 1.0 mg) was
suspended in EtOH (2% of final volume) and diluted with
deionised water (to a final volume of 1 mL). The suspension
was briefly sonicated (<10 s), stirred by vortex at 2500 rpm for
5 min, allowed to stand for 25 min and centrifuged (13 000g
for 10 min) before a sample was taken for analytical HPLC ana-
lysis (50 μL injected). HPLC runs were performed using iso-
cratic gradient of acetonitrile/H2O 50 : 50 at a flow rate of 1 mL
min−1 using a Phenomenex Gemini C18 column (110 Å, 5 μm,
250 × 4.60 mm). Calibration curves were constructed using 5
concentration points of 2-fold dilutions of an appropriate CTV
scaﬀold derivative in acetonitrile/H2O 50/50, v/v. The results are
a mean of three independent experiments performed in tripli-
cate. The solubilisation had to be aided by addition of 2% of
ethanol in order to break clusters of namely compound 21
which would otherwise barely interact with water. Even though
such addition alters the final solubility, the ratio of solubility
between the three scaﬀold derivatives should remain the same.
Log P determination
Following the OECD method,8 6 standards of known log P
(anisole, toluene, bromobenzene, phenyl benzoate, diphenyl
ether, bibenzyl) were used to construct a calibration curve.
Log P values of compounds 20, 21, and 22 were determined
from their retention time using regression equation obtained
from the calibration curve of standards. Analytical HPLC runs
were performed using isocratic gradient of acetonitrile/H2O
50/50, v/v at a flow rate of 1 mL min−1 using a Phenomenex
Gemini C18 column (110 Å, 5 μm, 250 × 4.60 mm). Dead
volume of the HPLC system was determined to be 2.89 min
using uracil.
Recombinant hTNFα expression
Soluble recombinant hTNFα (Val77 – Leu233) was obtained by
cloning its E. coli optimised gene sequence into a pDEST14™
expression vector (Thermo Fisher Scientific). The expression
vector was transformed into competent E. coli BL21-AI™ One
Shot® according to the manufacturer’s protocol. A single
colony of transformed cells was selected and allowed to
expand in 2-YT bacterial growth media (16 g of tryptone, 10 g
of yeast extract, 5 g of NaCl per 1 L supplemented with 50 μg
mL−1 carbenicillin; 20 mL) at 37 °C overnight with 165 RPM
shaking. The overnight bacterial culture was expanded into
fresh 2-YT media at a ratio of 1/20 and the culture was incu-
bated at 37 °C with 165 RPM shaking until the cells reached
log phase (approximately 2 h). The cells were then induced for
5 h with the addition of L-(+)-arabinose (final concentration of
0.2% w/v) to initiate protein expression. After induction, the
cells were pelleted by centrifugation at 12 000g for 5 min at
4 °C. The pellet was suspended in cold lysis buﬀer (20 mM
Tris-HCl, 1 mM EDTA, pH 8.0, supplemented with EDTA-free
protease inhibitor cocktail; 10 mL) and the cells were lysed on
ice by sonication (10 s with 25% amplitude followed by 30 s
break, repeated 15 times). The lysate was centrifuged at
12 000g for 15 min at 4 °C and the supernatant was transferred
into a new tube. The remaining pellet was resuspended in
fresh ice cold lysis buﬀer (10 mL) and the above procedure was
repeated and the supernatant was pooled. The hTNFα was pur-
ified from the supernatant using an optimised procedure from
Zhang et al.24 In short, the supernatant containing recombi-
nant hTNFα was applied on to two HiTrap™ DEAE Fast Flow
(GE Healthcare) columns with 10 mL of total column volume
(CV) using an AKTA Start purification system (GE Healthcare)
at a flow rate of 1 mL min−1. The columns were equilibrated
with 8 CV of buﬀer A (20 mM Tris-HCl, pH 8.0) and hTNFα
was eluted by applying 15% step elution gradient of buﬀer B
(20 mM Tris-HCl with 1 M NaCl, pH 8.0). The second purifi-
cation step was carried out on a HiTrap™ CM FF (GE
Healthcare) column with 5 mL of CV (equilibrated with 5 CV of
buﬀer C) after 1/5 dilution of hTNFα containing fractions from
DEAE column with buﬀer C (20 mM Na2HPO4/KH2PO4, pH
6.0) to decrease conductivity below 5 mS cm−1. Elution of
hTNFα was achieved by applying gradient (0%–30%) of buﬀer
D (20 mM Na2HPO4/KH2PO4 with 1 M NaCl, pH 6.0). Fractions
containing hTNFα were pooled and dialysed (benzoylated cell-
ulose, MWCO 2 kDa) against PBS pH 7.4 overnight at 4 °C. The
dialysed protein was sterile-filtered using a 0.2 μm filter and
aliquots were stored at −78 °C. The activity and purity of
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hTNFα was assessed by an MTT assay utilising L929 cell line
and SDS-PAGE respectively. Typically, 10 mg–14 mg of TNFα
with a purity ≥97% and IC50 of 0.07 ng mL−1 was obtained
from a 250 mL of bacterial culture.
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